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Neoadjuvant radiotherapy/chemoradiotherapy (N-RT/CRT) is frequently used to treat rectal 
cancer due to its ability to reduce tumour bulk prior to surgery. It has been shown to 
significantly reduce the recurrence of cancer and improve the anal structure integrity post-
surgery. However, radiotherapy is often associated with severe adverse effects, drastically 
reducing the quality of life. Additionally, some patients are subjected to these adverse effects 
with no positive outcomes as 30% have no response to N-RT/CRT. Therefore, it is essential to 
understand why tumours respond differently to a treatment. One way to explore this is to look 
at the molecular characteristics of cancers such as miRNAs involved in regulating gene 
expression and response to irradiation exposure. This study investigates the expression of 
miRNAs in response to irradiation exposure in a rectal cancer cell model. 
This study used the rectal cancer cell line SW837 to research miRNA as biomarkers of 
radiosensitivity. Usually, colorectal cancer research is conducted with the faster, more stable 
colon cancer cell lines. However, we believed researching a rectal cancer cell line would be 
more representative of rectal cancer because rectal cancers are genetically distinct from colon 
cancers. The characterisation of irradiation effects on cell viability was important to investigate 
as our lab had never worked on radiating cells before. SW837 is also relatively 
underrepresented in research. Therefore, optimisation of all assays was conducted to lay the 
foundation for future research. After irradiation characterisation, we studied the expression 
differences in a pre-selected miRNA panel of interest when exposed to different irradiation 




When characterising the cell viability, death, and apoptosis of SW837 cells exposed to different 
irradiation doses, a longer incubation post-irradiation incubation time produced the greatest 
distinction between doses. This was concluded that irradiation-induced cell responses occur 
the greatest after a full cell cycle has occurred. Therefore, an incubation time of at least 72-
hours was ideal as it was found that SW837 cells had a doubling time of 90-hours. Western 
blotting was used to detect γ-H2AX, a sign of irradiation damage. However, it failed to be 
detected using western blotting, highlighting the importance of correct protein loading.  
 
miRNA expression changes did not result in any statistically relevant data due to a lack of 
repeats. However, interesting changes were observed in two of the miRNA. miRNA-185-5p 
showed a decreased expression with increased irradiation dosing, while miRNA-23a-3p 
showed the opposite. Overall, though these results were not statistically backed, interesting 
changes to expression have started to appear, indicating areas to research. Furthermore, this 
study has optimised many assays to further research in our lab regarding irradiation exposure 
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CHAPTER 1: INTRODUCTION: 
 
1.1 COLORECTAL CANCER: 
1.1.1 PREVALENCE:  
Colorectal cancer (CRC) accounts for 1 in 10 cancer-related deaths worldwide, causing 
881,000 deaths in 2018 (1). New Zealand and Australia are currently second in the world for 
total CRC incidence, and CRC rates in women are disproportionally higher than any other 
country (1). Trends for CRC incidence in New Zealand have been worrying, rising from a 
prevalence of 27.3-37.0 per 100,000 in 1960-1969 to 48.4-57.3 per 100,000 in 1990-1999 (2). 
CRC has traditionally had the greatest impact in developed regions such as Australasia, with a 
10-fold difference in incidence and mortality compared to developing countries (1,3). With 
New Zealand experiencing an aging population, CRC incidence are likely to become inflated. 
Additionally, the worldwide burden of CRC is expected to increase 60% by 2030, indicating 
the immense burden this disease has and will have on health systems such as New Zealand’s. 
(3,4). 
1.1.2 RECTAL CANCER VS COLON CANCER:  
CRC was first classified by location in Beart et al. (1983) and Bufill (1990) (5,6), into colon 
and rectal cancers. Since then, this has been further stratified with the addition of recto-sigmoid 
cancers (7). According to the New Zealand cancer registry, 67.9% of CRCs are colon, 25.4% 
rectum, and 6.6% recto-sigmoid (7). There are mortality differences between colon and rectum 
cancers – globally, men have a 0.66% chance of dying from colon cancer compared to a 0.46% 




Rectum and colon cancers are inherently different due to several factors, and thus, should be 
treated as such. The colon and rectum are embryonically distinct organs, with the rectum 
originating from the hindgut, and the colon from the midgut and hindgut (9). Thus, they each 
have differences in location within the bowels (See Figure 1.). These locational differences 
cause colon and rectal cancers to behave differently e.g., metastatic patterns (10). Pihl et al. 
(1987) found 11.5% of rectal cancer patients had pulmonary metastasis compared to 3.5% of 
colon cancer patients (11). Their function also differs. The colon absorbs more sodium; thus, 
it has greater potential for water retention. Alternately, the rectum has a greater density of 
goblet cells and so secretes more mucin which protects the mucosal surface against chemical 
and physical trauma. Briefly, the genetic pathways in which cancer develops in colons and 
rectums are often distinct (9). Distal colon cancers are often driven via the chromosomal 
instability (CIN) causing the activation of oncogenes and inactivation of tumour-suppressor 
genes (12,13). Proximal colon cancers are often caused by microsatellite instability (MSI) 
which is a condition that increases the predisposition to mutations. MSI is associated with the 
familial disease, hereditary nonpolyposis CRC (14). On the contrary, rectal cancers 
demonstrated less dependence on family history (15), decreased MSI, increased CIN, and have 




Figure 1. Locations of Colorectal Cancers in the Bowels1 
1.2 TREATMENT OF RECTAL CANCER: 
Local treatment for rectal cancer is often more aggressive than for colon cancer. This is due to 
the sensitive location of the rectum, surrounded by nerves, major vessels, and genital organs. 
The current standard of care for rectal cancer is surgery, commonly a total mesorectal excision 
(TME). This is preceded by either neoadjuvant radiotherapy or chemoradiotherapy (N-RT or 
N-CRT), which is tumour, nodal, and metastatic (TNM) stage and risk dependent (See Figure 
2.) (17–19). TNM staging is used to determine the size, infiltration, and spread of cancers (19) 
(See Table 1.). N-RT/CRT administration is primarily dependent on the tumour size and nodal 
involvement, all of which are assessed using both endorectal ultrasound and MRI (20,21). N-
RT/CRT is currently given to stage II-IV tumours – those with tumour involvement in the 
mesolectal/ pelvic lymph nodes, or invasion into the perirectal tissues. Before N-RT/CRT and 
TME treatments, the chances of 2-year local recurrence of a locally invasive tumour was 20%, 
however, that has now fallen to 3-5% due to these interventions (14,22). 
  
Figure 2. Diagram of Diagnosis and Treatment Pathways for Rectal Cancer. 2 
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aWithin tumour, lymph and metastatic classifications are subclassifications  
bReferring to regional lymph nodes 
cTable referenced derived from (19) 
 
1.2.1 NEO-ADJUVANT THERAPY:  
There are currently three major N-RT/CRT options: short-course chemoradiotherapy (SC), 
long-course chemoradiotherapy (LC) and induction chemotherapy paired with LC (ILC). SC 
uses an external beam of irradiation at 5 Gray (Gy) per day for 5 days. LC uses 45 – 50 Gy of 
irradiation total over 25 – 28 days and is often administered to stage II patients. Finally, ILC 
uses the standard LC method but with the administration of 5-FU, leucovorin, and oxaliplatin 
in combination for 3 – 6 cycles before LC (23;24).  ILC is often administered to high-risk stage 
III, IV to target micro-metastatic spread. A study by Fernandez-Martos et al. (2011) found ILC 
to have similar survival and recurrence outcomes as LC but claimed that ILC had better 
completion rates and fewer side effects (25). The goal of N-RT/CRT is to downstage the 
tumour; thus, increasing the success rate of curative-intent surgery and preserving the anal 
continence and anal sphincters. In turn, this reduces the rate of recurrence. 
N-RT/CRT has been found to significantly improve rectal cancer recurrence rates. Kapitenijn 
et al. (2001) found that rectal cancer patients on SC had a 2.4% rate of local recurrence, while 
those on surgery alone had an 8.2% recurrence rate (p<0.001). Additionally, 30.5% of patients 
undergoing neoadjuvant therapy can experience a complete clinical response (cCR) – defined 
as a lack of tumour evidence via clinical and endoscopic examination at least 4 weeks post-N-
RT/CRT (26,27). These patients were then able to participate in the wait and watch scheme: a 
period of 36 months follow up, where patients do not undergo surgery, to determine if N-
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RT/CRT was successful alone in removing disease (26). Although, 50% of patients get a partial 
response to N-RT/CRT (28), and up to 30% have no response (29). Being able to stratify 
patients based on how the tumour would respond to N-RT/CRT might allow for a reduction in 
over- and under-treatment; thus, giving insight into who will have a cCR and who will have no 
response. This is especially important as it is known that RT and CRT have significant adverse 
effects, often contributing to a reduction in quality of life (QOL) (26).  
1.2.2 RISKS OF N-RT/CRT: 
N-RT/CRT has been associated with some serious adverse effects that decrease QOL. These 
complications have been divided into acute and long-term toxicities by a collaboration from 
the Radiation Therapy Oncology Group (RTOG) and the European Organisation for the 
Research and Treatment of Cancer (EORTC) (26). See Table 2. for a summary of toxicities; 
with an increasing grade (1-4) representing more harmful toxicities.   
Table 2. Grading of N-RT/CRT Induced Adverse Effects: (Derived from (26)) 2 
 
aPre 6-months post radiotherapy  
bPost 6-months post radiotherapy 
cPR (Post Rectum) 
 






















































Several studies observed the frequency of these adverse events post RT or CRT. In Sauer et al. 
(2014) they found 27% of their patients experienced acute grade 3-4 toxicities due to N-
RT/CRT. Additionally, 14% of patients experienced late irradiation toxicities such as acquiring 
a suture at the anastomosis site. The Stockholm III trial reported the incidence of adverse events 
was not significantly different between LC and SC treatments (30). Although, there is evidence 
that LC can cause a greater perineal wound breakdown and anastomosis leakage than SC 
(31;33). 
Diarrhoea was one of the most commonly reported toxicities of N-RT/CRT, with 14.2% and 
12% of patients reporting it in Ansari et al. (2017) and Sauer et al. (2004) respectively (31; 32). 
Other adverse effects reported post-N-RT/CRT that have a significant reduction in QOL are 
urinary and sexual dysfunctions, with Hendren et al. (2005) finding 29% of women and 45% 
of men experienced sexual dysfunction post-treatment (34). Pelvic fractures were another 
major defector to QOL caused by N-RT. It was found that RT increases osteopenia by causing 
a loss of mineralisation, which leads to stress fractures of the pelvis (35). 
The adverse events caused by radiotherapy in rectal cancer treatment put a significant burden 
on patients QOL. Therefore, it is vital to predict who will respond and who will not in order to 
reduce potential harm. Currently, the best practice to determine who will respond is by a 
clinician’s judgment – determining if the patient is fit and eligible to withstand N-RT/CRT. 
Clinically, there is a myriad of biomarkers to give insight into prognosis and predict response 
to certain treatments (36). However, there is currently a lack of clinical biomarkers that can be 
used to determine N-RT/CRT response, and with patients able to have either a cCR, or no 
response, it is important to develop stratifying biomarkers (37). 
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1.3 MIRNA AS A PREDICTIVE MARKER OF IRRADIATION 
RESPONSE: 
1.3.1 MIRNA AND CANCER: 
miRNAs main function are to regulate endogenous gene expression via the binding of 
messenger RNA (mRNA) sequences of the transcribed gene. This is possible due to miRNA 
being a conserved 20–25 molecules in length non-coding RNA and having a specific sequence 
to mRNA (38). miRNAs achieve this regulation by forming the RNA-induced silencing 
complex (RISC), which once bound to complementary mRNA will reduce protein expression 
via silencing translation or degrading the mRNA (38). miRNA have recently been associated 
with cancer progression, as the main genes they regulate are often involved in such 
tumorigenesis processes as proliferation, apoptosis, angiogenesis, migration and metastasis 
(39). 
Cancers can take advantage of the miRNA gene regulatory function in two main ways (See 
Figure 3.). 1) Via the upregulation of miRNA that is complementary to a tumour suppressor 
gene, downregulating the tumour suppressor and upregulating tumorigenesis. 2) Via the 
downregulation of miRNA that is complementary to an oncogene; thus, upregulating the 
oncogene to promote tumorigenesis (40, 41). Since miRNA are specific to several genes, the 
activity of them in cancers can give insight into what gene expression has been altered; 





Figure 3: Regulatory Mechanisms of miRNAs in Promoting Tumorigenesis 3 
Left demonstrates miRNA acting upon tumour suppressors. Right demonstrates miRNA 
inhibition to promote oncogene expression. 
 
An example of how miRNA can use the two methods to promote tumorigenesis is presented.  
The upregulation of has-miR-183-5p and has-miR-21-5p, paired with the downregulation of 
has-miR-195p and has-miR-497-5-p in CRC tumours was found to dysregulate APC, EGFR, 
MAPK family, AKT family, KRAS, TP53, and BRAF genes (42).  These genes are commonly 
found dysregulated in CRC, associated with increased tumorigenesis and development (43-45). 
Therefore, the aforementioned miRNA was concluded to increase CRC development via 
dysregulating the above-mentioned genes (42). 
When the function of an miRNA is determined in relation to increasing tumorigenesis, the 
miRNA expression can be used to determine how the cancer will behave. If a miRNA 
expression is linked to affecting how a drug or treatment functions, then its expression can be 
used to determine how effective that treatment would be.  A meta-analysis by Peng et al. (2017) 
looked at miRNA-21’s potential to predict and give insight on the prognosis and predictive 
power in CRC (46). It found the overall diagnostic predictive sensitivity to be 0.64 and 
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specificity to be 0.85. They found those with increased miRNA-21 to have a shorter overall 
survival. Thus, they concluded miRNA-21 to be suitable at providing diagnostic and prognostic 
information in CRC.  miRNA-31-3p is another miRNA analysed for its potential to predict 
therapy response in CRC. It was found that patients being treated with the anti-EGFR drug 
cetuximab had a greater progression-free survival if the miRNA-31-3p expression was lower 
and vice versa. This subsequently resulted in it becoming a clinical biomarker for adjuvant 
therapy success, with the test “miRpredX” by “IntegraGen” being developed (47).  
Using miRNA as a molecular biomarker is still early as a concept in research. A systematic 
review by Ma et al. (2012) compared the miRNA profiles of CRC tissue and non-cancerous 
tissue (48). They reported a total of 362 differently expressed miRNAs (120 downregulated, 
242 upregulated) in CRC tissue compared to normal.  
1.3.2 MIRNAS AND IRRADIATION RESPONSE:  
Ionising irradiation can cause cellular death via two main pathways: 1) The most common is 
by directly damaging the DNA causing double-stranded breaks (DSB). 2) A secondary effect 
is by producing reactive oxygen species that cause damage to cellular components such as HIF-
α, VEGF, and EGFR (49;50). The ionising irradiation-induced DSBs are the most responsible 
for cellular induced radiation death. Cellular mechanisms in response to DSBs can cause the 
cell to repair the DNA, induce cellular senescence, apoptosis, or result in cell death depending 
on the severity of the DSB (51). If the DSB cannot be repaired or results in incorrect repair, the 
cell must induce senescence or death to prevent producing daughter cells that may have 
mutations harming the organism, such as promoting cancer (51). However, cancers can 
influence pathways responsible for senescence, cell repair, and apoptosis by dysregulating cell-
cycle components such as p53, p21, p27 and apoptotic components such as BCL-2 and NF-kB 
(50). Thus, cancers can reduce irradiation and induce cell death, apoptosis, and senescence, 
conveying radioresistance and thus, reducing radiotherapy's effectiveness (52). 
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Cancers can alter the expression of certain miRNA to influence the mentioned signalling 
pathways to promote radioresistance. For example, miRNA-622 targets the tumour suppressor 
gene, retinoblastoma (RB1), which is involved in apoptosis and the cell cycle (53). A study by 
Ma et al. (2015) found in CRC cells of patients' pre-radiotherapy and post-radiotherapy 
irradiation-resistant cells, miRNA-662 was significantly increased in the latter. Additionally, 
when miRNA-662 was transfected into CRC cells, the RB1 expression decreased. When 
increasing miRNA-662 in CRC cells, they found a dose-response increase in irradiation 
resistance. Cancers have also been found to increase the expression of miRNA-21, which was 
found to downregulate the PI3K/AKT pathway. miRNA-21 induced downregulation of the 
PI3K/AKT pathway alters the cell-cycle progression to decrease irradiation-induced death 
(54). Additionally, it has also been found that some miRNA positively regulates irradiation 
response, sensitising cells to radiotherapy. These, however, are often downregulated in cancers 
rather than upregulated. miRNA-185 has been shown to increase radiosensitivity by 
downregulating the IFG1R and IGF2 pathways involved in proliferation and angiogenesis (55). 
Additionally, a systematic review by Izzotti et al. (2020) found miRNA-92a and miRNA-335 
to regulate the enzyme acid ceramidase (ASAH1) (56). Increased levels of ASAH1 in CRC 
cells has been associated with a poor N-CRT response. Researchers have attributed this to the 
ASAH1 catalysing the lipid ceramide, which builds up due to irradiation damage, further 
inducing apoptosis. (57). Thus, miRNA-92a and miRNA-335 have been found to be decreased 
in cancers, upregulating ASAH1, accelerating the cleavage of the tumour suppressor ceramide 
and reducing irradiation-induced apoptosis.  
 
As well as altering the irradiation-induced signalling pathways to convey radioresistance, 
miRNA expression can also directly decrease DSB repair. When DNA DSBs occur due to 
irradiation, the cell attempts to fix the DNA by producing the DNA damage response (DDR) 
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(58). The DDR involves many mechanisms that are endogenously influenced by miRNA to 
function. This regulation can involve abandoning repair if the damage is too critical. Thus, 
cancers can alter miRNA expression to alter the DDR in favour of survival, increasing 
radioresistance (58).   
Regardless of pre-treatment genetic and miRNA profiles, cancers can develop resistance to N-
RT (59). Similar to cancer resistance to drugs and other treatments, the driving force is 
heterogeneity within the tumour, selecting for mutations and gene expression favourable to the 
new temporal conditions (50). This can be exacerbated by irradiation damage leading to 
mutations. Therefore, even if cancers are not inherently radioresistant prior to radiotherapy, 
treatment can induce radioresistance. This demonstrates the importance to study miRNA and 
how the expression changes can influence a radiotherapy response.  
 
1.3.3 HOW THE MIRNA COULD BE USED AS A TARGET OF THERAPEUTIC 
TREATMENT:  
As well as miRNAs power to be used as predictive irradiation response, they can also be 
influenced in the cell to alter their expression, and thus to provide therapeutic outcomes. (60). 
miRNAs that are overexpressed in cancers to induce tumorigenesis can be inhibited and/ or 
degraded to reduce the oncogenic effects in which they contribute. This can be achieved with 
several techniques, although none are FDA approved yet. One example is antisense anti-
miRNA oligonucleotides, which function to inhibit miRNA by binding to and altering its 
structure, becoming unrecognisable (61). On the contrary, miRNA that act as tumour 
suppressors can provide an anti-cancer effect by artificial induction in cancer cells. An example 
of such is MesomiR-1, a miRNA-16 mimic, which when induced in cells applies a protective 
factor against cancer (62). These ideas could be transferred to any identified miRNA 
biomarkers in N-RT/CRT response, potential producing a therapeutic to sensitize irradiation 
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resistant cancers; thus, improving treatment. More examples will be discussed concerning the 
specific miRNA panel of interest. 
1.4 MIRNA PANEL OF INTEREST:  
It is vital to study how miRNA expression alters the irradiation response in cancer cell culture 
to inform potential areas of future research regarding how these miRNAs can be sued to predict 
radiotherapy response. This study has set out to evaluate the miRNA miRNA185-5p, miRNA-
23a-3p, miRNA-26b-5p, and miRNA-25-3p, and in particular, how they influence irradiation 
sensitivity in rectal cancer, and their utility as a potential predictive biomarker of radiotherapy 
response and therapeutic target. This panel was chosen based on previously conducted work of 
our laboratory comparing differentially expressed miRNA in the circulation of patients who 
responded and did not respond to CRT 
1.4.1 MIRNA-185-5P: 
miRNA-185-5p was investigated in this study as it has shown previous correlation with 
chemoradiation response in patients in studies conducted by our lab. miRNA-185-5p is an 
immunometabolic miRNA, which has been found to have regulatory effects on serine 
hydrolase enzymes, altering the metabolism of lipids and endocannabinoids (63). miRNA-185 
has also been found to have a protective factor against some cancers, as a study by Yin et al. 
2018 found it to inhibit prostate cancer angiogenesis induced by some pathways (64). 
Furthermore, a study by Komiya & Habas 2008 found that in breast cancers, miRNA-185 was 
negatively correlated with tumour size, tumour differentiation, and lung metastasis (65). In 
CRC, miRNA-185 expression was decreased, with an increase in miRNA-185 correlated with 
decreased proliferation (55). Proliferation was concluded to stem from miRNA-185 
suppression of the Wnt/β-catenin signalling pathways, which are associated with cancer when 
upregulated (65). High miRNA-185 expression was correlated with poor patient survival when 
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paired with low miRNA-33b (66). However, most relevantly, it has been found to enhance the 
radiosensitivity of CRC cells via the downregulation of the IFG1R and IGF2 pathways (55).  
1.4.2 MIRNA-23A-3P: 
miRNA-23a-3p was investigated in this study as it has shown previous correlation with 
chemoradiation response in patients in studies conducted by our lab. Considered one of the 
most studied miRNAs regarding human cancer, miRNA-23a-3p has much potential as a 
biomarker of irradiation response. A review by Wang et al. 2011 found that miRNA-23a in 
human biofluid can be a sensitive and specific biomarker of cancer and circulating miRNA-
23a as a biomarker for patient prognosis and predictive factor to cancer treatments (67). 
miRNA-23a function has been linked to regulating genes that increase tumorigenesis, cell 
migration, and invasion and induce drug resistance (68-71). Conversely, its upregulation in 
different cancers has decreased cell migration and invasion (72). More relevantly, increased 
miRNA-23a serum levels have been correlated with CRC (73). Additionally, a study by Yong 
et al. 2014 found that miRNA-23a in CRC was linked to the inhibition of apoptosis, while the 
inhibition of miRNA-23a in CRC cells was linked to cell death (74). Furthermore, in CRC, 5-
Fu treatment induced miRNA-23a expression, resulting in chemoresistance to 5-Fu (75). In 
contrast, Jin et al. 2015 found that an under expression of miRNA-23a was associated with 
increased chemosensitivity in ovarian cancer cells towards cisplatin treatment (76).  
However, most reverently to this study, it has also been found to induce radiosensitivity in 
Nasopharyngeal carcinoma (NPC), with a downregulation of miRNA-23a seen in 
radioresistant NPC cells. Additionally, increasing the expression of miRNA-23a in NPC cells 
facilitated NPC death via radiotherapy (77). However, further research is needed regarding the 
association between miRNA-23a expression and chemosensitivity and cell migration as no 




miRNA-26b-5p was thought to be consistently downregulated in cancers, such as breast and 
lung cancers (78; 79). Known to be associated with increased apoptosis of breast cancer cells, 
when unrepresented in cancers, miRNA-26b-5p reduces apoptosis and increases tumorigenesis 
(79). However, it was recently found that overexpression of miRNA-23b in CRC was 
associated with higher metastatic rates and invasion by promoting epithelial-mesenchymal 
transition (80). In contrast, miRNA-26b was found to have tumour-suppressive properties in 
CRC cells. Specifically, metastatic CRC cells have lower miRNA-26a expression than primary 
CRC cells, indicating anti-metastatic properties (81). These contradicting results in CRC 
demonstrate a contention in miRNA study due to the inability to replicate many results. 
Importantly, miRNA-26b was found to mediate decreased radioresistance in pancreatic cancer 
(82). However, research in how miRNA-26-5p is associated with CRC radiotherapy response 
is primitive and under researched. Therefore, a great deal of importance to research miRNA-
26-5p exists regarding radiotherapy response and its uses as a potential biomarker. 
1.4.4 MIRNA-25-3P: 
miRNA-25-3p is a well-known oncogenic miRNA overexpressed in lung, breast, and 
colorectal cancers (83). Specifically, it was found that miRNA-25 was overexpressed in CRC 
tumour samples and serum samples. Furthermore, increased miRNA-25 was associated with 
increased cancer progression and worsening patient prognosis (84). miRNA-25 was also found 
to mediate an inflammatory factor that increases carcinogenesis in CRC (85). Interestingly, 
miRNA-25 was found to be overexpressed in radiotherapy-resistant non-small cell lung cancer 
cells, compared to radiosensitive cells. However, research into the miRNA-25 effect on CRC 




1.6 AIMS AND OBJECTIVES: 
Exploring the role of miRNAs in rectal cancer in response to irradiation may provide insights 
into the molecular mechanisms of irradiation resistance. This can inform miRNA biomarker 
and therapeutic research. Herein, we explore two first steps in the research of a panel of how 
miRNA expression can influence irradiation response.  
 1) To establish a relevant cellular model of rectal cancer and irradiation exposure via 
characterising and optimizing assays that determine rectal cancer cell culture viability, death, 
and apoptosis post-irradiation. Additionally, to confirm irradiation as a cause of cell death via 
the detection of DSB using γ-H2AX expression. With importance to developing methods that 
are known to accurately record these properties in SW837 cells for future irradiation research. 
2) to determine the expression change of miRNA185-5p, miRNA-23a-3p, miRNA-26b-5p, and 
miRNA-25-3p when subjected to increasing doses of irradiation. Specifically, initiating 
research regarding how these miRNA affect the irradiation response of SW837 cells. 
We hypothesised that accurate and repeatable methods of characterising irradiation induced 
cell death and double stranded DNA breaks would be produced. Additionally, the miRNA 
panel of interest will demonstrate a change in expression when subjected to irradiation in rectal 
cancer cells. Indicating that the miRNA is correlated with irradiation sensitivity or resistance, 
leading to potential further research to confirm and build on these concepts.  
The results from this pilot study will allow us to understand if any of the miRNA in the panel 
of interest could be correlated to irradiation response in a rectal cancer cell line. This could be 
used to indicate where further research should be conducted. Ultimately, this study could lead 
to the expression of certain miRNA being used as an indicator of radiotherapy response; 




CHAPTER 2: MATERIALS AND METHODS: 
 
2.1 SW837 CELL CULTURE: 
2.1.1 CELL LINE: 
The human stage 4 adenocarcinoma rectal cancer (SW837; ATCCCL235) cell line was 
acquired from the American Type Culture Collection (ATCC), supplied by In Vitro 
Technologies. The cells are a rectal cancer cell line positive with a p53 mutation. SW837 cells 
were cultured in RPMI 1640 medium (Gibco:11875), supplied by ThermoFisher Scientific. 
RPMI media was supplemented with 10% foetal bovine serum (FBS; 54827) provided by 
Moregate Biotech, as well as 1% penicillin-streptomycin (10,000 U/mL) (Gibco:15140) 
supplied by ThermoFisher Scientific. The media was changed every 2-3 days. 
2.1.2 SW837 CELL GROWTH: 
Flasks were needed to be at a specific cell confluence to ensure accuracy during irradiation. 
Therefore, it was needed to understand the growth rates of SW837 cells at different seeding 
densities. We produced images of cells growing in T25 flasks at time points of 24-hours, 48-
hours, 98-hours, and 144-hours post-seeding to get cell growth data using 4x magnification 
microscopy. This counting method was decided, as lifting cells to count was not feasible, as it 
was wanted to measure the same flask at different time points. These images were then analysed 
using the software ImageJ.  
A macro program was developed to run the same processing and analysis on each image to 
ensure it was constant between images. The macro script is as follows:  










run("Convert to Mask"); 
run("Analyze Particles...", "pixel show=Outlines clear summarize"); 
This macro would convert the image to be more readable by computers. Then, the macro would 
run a predetermined threshold, "Yen dark," which determines what to read and not (86). This 
threshold results in the cells being filled as black, with no cell areas void of pixels. A pixel 
count was then run to determine the relative confluency of flasks. This functions if the 
magnification is constant and cell size is roughly the same between cells. For each data point 
collected, three images were taken at different locations on the flask as repeats.  
2.1.3 SW837 CELL CULTURE PROTOCOL:  
Cell stocks were grown in T-175 (175 cm2) to 80-90% confluence and passaged into 30 T-25 
flasks for experiments. Each t25 flask was seeded with approx. 50% of its cells at confluence 
in 3mLs of RPMI media, incubated for 24-hours and irradiated. Additionally, one T75 (75 cm2) 
flask was passaged from the t175 flasks to grow up into three t175 flasks to repeat the 
procedure. All cell culture flasks were incubated at 37⁰C in 5% CO2. 
Cells were passaged by splitting t175 flasks into t25 flasks when stock flasks became 80-90% 
confluent. Passaging was conducted by removing media from flasks, washing with PBS and 
using 0.25% Trypsin-EDTA solution (59438C), acquired from Sigma-Alrich, in 3 mL for T-
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25 flasks, 5 mL for T-75 flasks, and 17 mL for T-175 flasks. Trypsin-EDTA solution was left 
on the cells for 5 minutes in an incubator at 37⁰C in 5% CO2, following this, flasks were 
agitated, and trypsin was neutralised with equal parts media. Cells were then pelleted and 
resuspended in media to be seeded into new flasks, and media was replaced the following day. 
2.1.4 CELL CONCENTRATION IN MEDIA: 
Cells need to be seeded at appropriate cell densities to ensure accuracy in assays. Therefore, to 
gauge cell concentration in media, the Luna II™ Automated Cell Counter was used, which 
recorded cell size and viability paired with trypan blue stain to get a cell count. Cell counts 
were conducted by pooling the cell media solution from the 3 T-175 flasks and taking two 
measurements, which were then averaged. This was conducted twice to ensure accuracy 
2.2 IRRADIATION OF SW837 CELLS: 
Radiation of the SW837 cells was conducted at the Malaghan Institute of Medical Research in 
Wellington, New Zealand. SW837 cells were seeded 24-hours before irradiation in t-25 flasks. 
Cells were seeded to be at 50% confluent on day of irradiation; thus, exponentially growing. 
Irradiation of cells used doses of 0, 2, 4, 6, 8, and 14 Gy, conducted with Cesium-137 γ-rays 







Figure 4: Diagram of post-radiation Procedure. 4 
Ten of the 30 flasks were used for a CCK-8 assay (SET 2), ten were used for miRNA analysis 
and western blot assay (SET 1), and the final ten were used for flow cytometry assay (SET 3) 
(See Figure 4.). Each irradiation dose was performed in duplicate. The first irradiation event 





2.2.1 IRRADIATION EVENTS: 
Each repeated irradiation of cells was recorded as an irradiation Event (RE). They differed in 
methodology due to optimization (See Table 3.). After irradiation exposure, sets 1 and 2 were 
incubated at 37⁰C in 5% CO2 for alternating times depending on RE. Set 3 had alternative lysis 
buffer addition protocols between RE as a process of troubleshooting the western blotting 
protocol.  
Table 3: Irradiation Event Changes: 3 
RE:  Total cells in each T25 Post-radiation 
Incubation Time 
(hours) 
Set 3 lysis addition 
1 9.27x105 38 Delayed a 
2 4.92x105 24 Immediate b 
3 1.37x106 72 Immediate 
a Lysis buffer was added 30 minutes after irradiation of cells  
b Lysis buffer was added immediately after irradiation of cells 
 
2.3 MIRNA ANALYSIS (SET 1): 
2.3.1 MIRNA ISOLATION AND QUANTIFICATION: 
Radiated SW837 cells in the ten flasks for flow cytometry analysis and miRNA quantification 
analysis were lifted via trypsin, centrifuged, and resuspended in RPMI media. Following this, 
the samples were separated into miRNA assay and flow cytometry aliquots. The miRNA 
aliquots were spun down again and resuspended in lysis/ binding buffer derived from the 
miVana™ miRNA Isolation Kit (Invitrogen: AM1560), sourced from ThermoFisher. Samples 
were either used immediately or were frozen at -80℃ until needed.  
 
RNA was isolated from cell lysates using the mirVana™ miRNA Isolation Kit with phenol 
(Invitrogen: AM1560), sourced from ThermoFisher. The standard manufacturers’ protocol for 
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total RNA isolation cell culture samples was used, disregarding the enrichment procedure for 
small RNAs. RNA purity and quaintly was analysed using NanoDrop™ Spectrophotometry. 
2.3.2 NANO DROP QUANTIFICATION AND QUALIFICATION:  
Before miRNA can be further processed, samples are required to be diluted to 5 ng/ul. 
Concentrations of RNA were obtained by running samples on a NanoDrop™ which gave total 
RNA quantity and quality. RNA quantity data was used to produce dilutions using RNase-free 
water as the dilutant.  
NanoDrop™ derived RNA quality readings were used to assess samples for contamination. 
Quality was determined via the 280/260 nm ratios. These ratios are derived from nucleic acid 
having a maximum absorbance of 260 nm, while proteins have a maximum of 280 nm. 
Therefore, a 260/280 nm ratio of around two is deemed high quality for RNA.  
2.3.3 CDNA SYNTHESIS AND AMPLIFICATION: 
Total miRNA was converted to cDNA prior to amplification, and real-time PCR (RT-PCR) as 
cDNA is more stable than RNA. The conversion was achieved via reverse transcription using 
the TaqMan™ Advanced miRNA cDNA Synthesis Kit (Applied Biosystems: A29007), soured 
from ThermoFisher.  
2 uL of the diluted sample was added to the poly[A] tailing reaction mixture and run using the 
poly [A] tailing reaction thermal cycler routine. See Table 4. for all the reaction mixture 
components and thermal cycler routines. After the poly[A] tailing reaction, 10 uL of the adaptor 
ligation reaction mixture was added to each sample. The corresponding thermocycler routine 
was then run. After the adaptor ligation reaction, 15 uL of the reverse transcription mixture was 
added to the subsequent mixture and run on the thermal cycler with the reverse transcription 
routine. After cycling, 5 uL of the reverse transcription mixture was added to the 45 uL miR-




Table 4: Reaction mixture components and thermocycler routine: 4 




- 0.5 uL 10 poly[A] buffer 
- 0.5uL ATP mixture  
- 0.3 uL Poly[A] enzyme mixture 
- 1.7 uL RNase-free water 
37℃ for 45 minutes, followed 
by 65℃ for 10 minutes, 




- 3 uL 5X DNA ligase buffer 
- 4.5 uL of 50% PEG 8000 
mixture 
- 0.6 uL of 25X ligation adaptor 
mixture 
- 1.5 uL of RNA ligase mixture 
- 0.4 uL of RNase-free water 
16℃ for 60 minutes, followed 




- 6 uL of 5X R.T. buffer 
- 1.2 uL of dNTP mixture 
- 1.5 uL of 20x universal R.T. 
primer 
- 3 uL of 10X R.T. enzyme 
mixture 
- 3.3 uL of RNase-free 
42℃ for 15 minutes, followed 




- 25 uL 2X miR-Amp master 
mixture 
- 2.5 uL of 20X miR-Amp primer 
mixture 17.5 uL of RNase-free 
water 
95℃ for 5 minutes, followed by 
the sequence of 95℃ for three 
seconds and 60℃ for 30 seconds 
repeated 13 times. After the 
aforementioned sequence, the 
reaction mixture was subjected 
to 99℃ for 10 minutes, followed 
by a 4℃ hold. 
 
 
2.3.4 REAL-TIME PCR: 
RT-PCR was used to quantify the relative expression of miRNA-185-5p, miRNA-25-3p, 
miRNA-26b-5p, miRNA-185-5p, miRNA-335-5p, and miRNA425-5p using specific primers 
for each. The TaqMan™ Fast Advanced Master Mix (Applied Biosystems: 4444963), sourced 
from ThermoFisher, was used in conjunction with the Bio-rad CFV384 qPCR System (Bio-
Rad) to facilitate RT-PCR. The cDNA mixture produced prior was diluted in a 1 in 10. 5 uL of 
diluted cDNA mixture was added to 15 uL of the PCR reaction mixture. A separate PCR 
reaction mixture was produced for each miRNA, differing due to the different miRNA primers. 
PCR reaction mixtures consisted of 1 uL of the specific TaqMan® advanced miRNA assay 
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(20x) (miRNA primer), 10 uL of TaqMan® advanced master mixture (2X), and 4 uL of RNase-
free water. This was then run on the Bio-rad CFV384 using the 7500 and 7500 fast systems 
functions. Specifically, samples were run at 95℃ for 20 seconds, followed by the sequence of 
95℃ for 1 second and 60℃ for 20 seconds repeated 40 times. RT-PCR resulted in Cq values, 
which were then analysed.  
2.3.5 DATA ANALYSIS: 
RT-PCR resulted in threshold cycle values (Cq), interoperated as relative quantification in this 
study. The threshold cut-off of Cq was set to 35 cycles, as miRNA that takes more than 35 
cycles to exponentially grow is deemed too low to not be contamination. Each sample was run 
in duplicate, with the maximum acceptable Cq difference between duplicates set to 1. If 
acceptable, the averaged Cq values were averaged and normalised using the geometric means 
of miRNA-335-5p and miRNA-425-5p; known housekeeper genes from previous studies of 
the department, which gave us ΔCq values. Lastly, the ΔCq fold change difference to the lowest 
ΔCq was calculated and presented in figures.  
Statistical analysis was used to make comparisons of each miRNAs relative expression 
between SW837 cells subjected to different doses of irradiation using the statistical software 
GraphPad prism. Groups were independent of each other; thus, unpaired t-tests and F-tests 
were used to determine any statistical differences and variation between groups. The threshold 
of T-test statistical significance was set to a p > 0.05. 
2.4 FLOW CYTOMETRY DETECTION OF CELL DEATH AND 
APOPTOSIS (SET 1): 
The flow cytometry aliquots were pelleted and resuspended in new media, followed by a re-
pellet. The pellet was then resuspended in 1mL of FACS buffer (PBS + 2%FCS + 2.5 mM 
35 
 
CaCl2, pelleted, and resuspended in the same. 85 uL of each suspension of the different 
irradiation doses was transferred to an array of test tubes for each staining procedure. 
2.4.1 STAINS:  
The stains used were Alexa Fluor® 647 Annexin V (6409), sourced from BioLegend, for the 
staining of apoptotic cells. Additionally, Propidium Iodide Solution (421301), sourced from 
BioLegend, was used to stain non-specific dead cells. Alexa Flour® has a maximum emission 
of 668 nm when excited at 633-635 nm. Propidium Iodide Solution is excited at 488 nm and 
detected using the E/ Texas Red® channel, paired with a bandpass filter of 610/10. Initial 
experiments done were for optimising the dilutions of stains. The flow cytometer used had a 
side-fluorescence light maximum intensity of 107; therefore, stains will need to be diluted to 
fall within this range. A 1:5, 1:10, and 1:50 dilutions were initially conducted to determine the 
most detectible staining range. However, this resulted in a very high-intensity stain for both 
annexin V and propidium iodide. Therefore, another dilution range of stains was conducted, 
using 1:25, 1:50, 1:100, and 1:200 dilutions. From this, it was concluded that annexin V should 
be used at a dilution of 1:200, and propidium iodide at 1:500 for optimal stain intensity for our 
cells and flow cytometer. 
2.4.2 STAINING PROCEDURE:  
To different 85 uL samples, the staining procedures are as follows: 1) One tube for full staining 
of both 5 uL Annexin V and 10 uL propidium iodide; this is for the main analysed data, either 
dilution or radiated data 2) One tube for single staining of 5 uL annexin paired with 15 uL 
FACs buffer, or 10 uL of propidium iodide paired with 5 uL of FACS buffer. Single stain tubes 
are also heat-killed via exposure to 65⁰C for 10 minutes, giving use as a positive control and 
allowing for positive/ negative stain gating to allow for the separation of stains in combined 
stained tests. Heat killing is used as a positive control as the cells are subjected to known cell 
killing environments, allowing for the binding of annexin and propidium iodine 3) Two 
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unstained samples are produced by only adding FACS buffer (one is heat-killed, and the other 
is not). These unstained samples allow for negative controls, allowing for better gating of 
positive stain readings, removing background fluorescence. Additionally, they can also be used 
to determine the forward (FSC) and side scatters (SSC) and the respective thresholds. 
2.4.3 FLOW CYTOMETRY: 
Samples were analysed on a Cytek® Aurora flow cytometer, with three lasers installed. The 
software used to communicate with the flow cytometer was SpectroFlow®. Using the 
SpectroFlow® software on the unstained samples, it was found the optimal threshold 
parameters to be 30 for FSC and 20 for SSC-a and SSC-b. These thresholds were kept constant 
through all experiments. Another set up within software included the fluorescence absorbance 
being set to the P.E. Texan Red channel to detect propidium iodide and the AF-647 channel for 
Annexin-V. 
Additionally, reference groups using the single stain samples of each stain and unstained 
samples were produced. Reference groups are important for the unmixing and gating of each 
stain within the fully stained samples. The stopping gate for these groups was set to "P1" under 
acquisition. After running all samples using SpectroFlow® and unmixing/ gating negative and 
positive staining, the data was exported to raw and unmixed, with unmixed being further 
analysed. 
2.4.4 ANALYSIS: 
Unmixed data were analysed with the software FlowJo, provided by BDbiosciences. This 
allowed for the production of scattergrams, which demonstrate a cell via a point on a grid, 
located based on its FSC, SCC, or side-fluorescence light (SFL). FCS is the recorded forward 
scattered light, indicating the relative size of a cell. SCC is the recoded side scattered light, 
indicating the internal complexity (87). FSC and SCC are independent of staining, unlike SFL, 
which is specific to each stain and indicates the staining intensity. A greater annexin-V 
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fluorescent intensity of a cell demonstrates its potential of undergoing apoptosis, while a 
greater propidium iodide intensity demonstrates the potential of being necrosed. 
Scattergram gating around the population of interest cells was produced using the unstained 
sample. The population of interest rate was applied to all samples, including the single stained 
positive controls and samples of interest. Subsequently, positive stain thresholds were 
determined by producing a positive stain gait using the two single-stained positive control 
samples (Annexin-V and P.I.). This gate was then applied to all sample scattergrams to produce 
a number of cells deemed positively stained for either stain. This was then produced into tables 
via determining the percentage of cells positive for each stain in each sample to the total cells 




Figure 5: Flow Cytometry Representative Images for A Conserved Process5 
Images taken from irradiation Exposure Event 2. Images of radiated or heat-killed (HK) 
SW837 cells stained with Propidium Iodide (PI), and/ or Annexin-V, or neither. A) 
Demonstrates HK unstained SW837 cells FSC compared with SSC. Gaiting around cells of 
interest (likely SW837 cells). B) Annexin-V only stained HK SW837 cells. Comparison of stain 
fluorescence and SSC. Used to gate around considered positively stained Annexin-V cells. C) 
PI only stained HK SW837 cells. Comparison of stain fluorescence and SSC. Used to gate 
around considered positively stained PI cells. D) Demonstrate of radiated SW837 cells, 
comparing PI fluorescence and SSC. Note the considered PI positive box derived from C. E) 
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Demonstrates HK SW837 cells unstained of both PI and Annexin-V. Shows PI fluorescence 
compared to SCC, to demonstrate it considered a negative control.  
 
2.5 CELL VIABILITY ANALYSIS USING CCK8 (SET 2): 
The Cell Counting Kit-8 (CCK-8) measured the relative cell population metabolic activity 
between flasks of different irradiation exposure; used to indicate how irradiation was affecting 
the viability of the SW837 cells. A CCK8 assay is a colourimetric assay that uses formazan 
dye produced by metabolically active cells as an indicator of viability. 
To ensure the accuracy of comparisons between flasks, each flask was seeded with the same 
number of cells with the same media volume. CCK-8 (ab228554) was sourced from Abcam. 
T-25 flasks were left in the incubator at 37⁰C in 5% CO2 for either 38hrs, 24hrs, or 72hrs 
depending on the aforementioned RE, prior to the administration of 250 uL of CCK-8. After 
CCK-8 was added, flasks were returned to the incubator for 4hrs wrapped in tinfoil. Post-
incubation, the absorbance at 460nm was measured for each flask, giving the relative cellular 
viability. Absorbances were normalised to a media only control. 
2.6 Γ-H2AX DETECTION USING WESTERN BLOTTING (SET 
3) 
2.6.1 LYSIS BUFFER ADDITION: 
Before a BCA or Western blot could be conducted on Set 3 flasks, SW837 cellular protein had 
to be released with the addition of a lysis buffer. The lysis buffer used was the exosome 
resuspension buffer taken from the Total Exosome RNA & Protein Isolation Kit (4478545; 
Invitrogen). This lysis buffer was supplemented with 1% phosphatase inhibitor (Halt™: 78420) 
and 1x protease inhibitor (Thermo Scientific™: A32963). These inhibitors were used to ensure 
γ-H2AX is not naturally degraded after the irradiation exposure to the cells, allowing for its 
detection via western blotting.  
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Prior to lysis addition, media was removed, and cells washed with PBS. The lysis buffer was 
then added to cells at different times post-radiation (See Table 3.). Following lysis addition, 
flasks were scraped while being kept at 4⁰C, and then aliquoted into Eppendorf tubes for a BCA 
assay or storage.  
2.6.2 BCA: 
A Bicinchoninic acid assay (BCA) was used to determine the total concertation of protein for 
each irradiation flask sample to allow for equal protein concentrations during western blotting.  
The Pierce™ BCA Protein Assay Kit (23225) was used for protein quantification, sourced from 
ThermoFisher Scientific; the standard manufacturer's protocol was followed to produce the 
standard curve and measure samples. The optimal working reagent ratio was 50:1 (50 parts 
reagent A, 1 part reagent B). Standard curves were produced using Albumin standard ampules 
diluted in lysis buffer (used in the samples) to produce a 20-2,000 ug/mL working protein 
range. Finally, a separate standard curve was produced for each plate read of samples. See 
Figure 6. for an example. Samples and standards were read on a 96 well plate at an absorbance 
of 562nm. The BSA assay allowed for the dilution of each sample to a specific concentration 




Figure 6: BCA Standard Curve example for SW837 Radiated cells, irradiation Exposure 
Event 16 
Standard protein concentration produced using Albumin Standard diluted in lysis buffer. 9 
concentrations produced: 2000, 1500, 1000, 750, 500, 250, 125, 25, 0 (blank) μg/mL. 
Duplicates of absorbance reading for each sample used, then averaged. Zeroed to blank. R2 
= 0.991, y = 0.0011x. Equation for calculating protein concentration from absorbance = 
Protein conc = x/ 0.0011 
2.6.3 WESTERN BLOT: 
Western blotting was conducted to determine the presence and relative concentration of γ-
H2AX in samples of radiated cells. The protocol used was derived from our lab Western Blot 
protocol with modifications for the specific samples and antibodies used here.  
Western blot polyacrylamide gels used were Novex™ WedgeWell™ 4-20% acrylamide Tris-
Glycine 1.0 mm 15-well Mini Protein Gels, sourced from ThermoFisher, (Invitrogen: 
XP04205BOX). The ladder used for protein size estimation was the Spectra™ Multicolor 
Broad Range Protein Ladder, sourced from ThermoFisher (Thermo Scientific: 26623). Lastly, 
the protein size range for the ladder is 260 kDa to 10 kDa, which covers the size of both γ-
H2AX at 15 kDa, and b-actin at 42 kDa. 
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2.6.4 GEL LOADING: 
 
Each sample well was loaded with 30 μL of the sample mixture. The mixture consisted of a 24 
uL diluted sample, diluted in PBS to reduce protein concentration to 0.8 ug or 1.5 ug, and 6 uL 
of Pierce™ Lane Marker Reducing Sample Buffer, sourced from ThermoFisher (Thermo 
Scientific: 39000). The sample mixture was heated at 95⁰C for 5 minutes prior to loading. Each 
ladder well was loaded with 10 uL of the ladder. 
2.6.5 GEL ELECTROPHORESIS AND BLOTTING: 
Proteins were subjected to either 120 volts for 90 minutes or 100 volts for 45 minutes, 
depending on the irradiation exposure event and troubleshooting assays.  Novex™ Tris-
Glycine SDS (TGS) running buffer was used at 1x to facilitate the gel electrophoresis. 
Blotting was conducted using Power Blotter Pre-cut Nitrocellulose Membranes and Filters, 
sourced from ThermoFisher (Invitrogen: PB7320), and soaked in Pierce™ 1-Step Transfer 
Buffer (Thermo Scientific: 84731).  A power blotter was used at either default blotting settings 
for a large range of molecular weights or the low molecular weight setting at 25 volts, 1.3 amp 
for 5 minutes. 
2.6.6 BLOCKING AND BLOT STAINING: 
After blotting, the nitrocellulose membrane was washed three times for 5 minutes in 1x Tris-
buffered Saline and Tween (TBST). The nitrocellulose membrane was then blocked using 
either 5% or 3% BSA diluted in TBST at room temperature, rocking for 1 hour, reducing the 
non-specific binding of antibodies. 
The antibody used for the staining for γ-H2AX was the Phospho-Histone H2A.X (Ser139) 
monoclonal antibody (3F2) sourced from ThermoFisher (Invitrogen: MA1-2022). B-actin was 
stained as a protein normaliser to allow for relative quantification of γ-H2AX. The B-actin 
monoclonal antibody (AC-15) sourced from ThermoFisher (Invitrogen: AM4302) was used. 
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Both primary antibodies were paired with an IgG (H+L) Goat anti-Mouse, HRP secondary 
antibody, sourced from ThermoFisher (Invitrogen: 626520). 
Initial dilution optimisation assay for the antibodies consisted of γ-H2AX primary antibody 
dilutions of 1:200, or 1:500 paired with secondary antibody dilutions of 1:2000, or 1:4000. B-
actin dilution optimisation was kept at stock, as this is most commonly used, while the 
secondary antibody dilution was at either 1:2000 or 1:4000. Post-optimization, the γ-H2AX 
primary antibody dilution was kept a 1:200, while the secondary antibody dilutions for γ-H2AX 
and B-actin were kept a 1:4000. 
Primary staining of γ-H2AX and B-actin was conducted by covering the nitrocellulose 
membrane with the respective antibodies and left rocking at 4⁰C overnight. The primary 
antibody was then removed, followed by the secondary antibody being applied and left rocking 
at room temperature for 1 hour. N.B. antibodies were reused multiple times and stored in the 
fridge.  
2.6.7 DEVELOPING AND IMAGING: 
For developing the nitrocellulose membrane, the SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate kit was used, supplied from ThermoFisher (Thermo Scientific: 
34580). The developing mixture was made up by mixing 6 mL of each reagent from the kit 
with 2 mL of distilled water. Each membrane was developed in the dark for 5 minutes before 
being instantly imaged using a membrane imager, where exposure and contrast were altered on 
a per-membrane case. 
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2.6.8 TROUBLESHOOTING PROTOCOL: 
 
Figure 7: Demonstration of the process of troubleshooting the Western Blot Protocol7 
All changes were additive, therefore, western blots conducted after the previous incorporated 
the previously applied changes as well as the new. 
 
2.6.9 COOMASSIE BLUE: 
An extra 20% Tris-glycine gel, following the previous western blot gel loading methodology, 
was produced for Coomassie Brilliant Blue staining. For staining, SimplyBlue™ SafeStain 
(Invitrogen: LC6060), sourced from ThermoFisher, was used. The standard manufacturer's 
protocol was used for staining, covering the gel in the stain for 1 hour, followed by three 1-





CHAPTER 3: RESULTS: 
3.1 SW837 CELLS CHARACTERISTICS AND GROWTH 
RATE: 
3.1.1 SW837 CELL GROWTH RATE: 
To optimise cell seeding density for irradiation assays, we first assessed SW837 growth rate at 
a range of seeding densities and time points. This was to ensure cells were confluent enough 
for irradiation. Additionally, cell growth rate was used to determine the doubling time of cells 
to gauge a long enough incubation time for cells to double. Using the ImageJ macro program 
described in methods, it successfully produced relative cell confluence from pixel counts. 
Three photographs taken at different locations of each flask used a microscopic magnification 
of (4x). The threshold used was Yen Dark, it appeared to capture most of the cell area of each 
image, resulting in accurate relative measures (see Figure 8.).   
                                 
Figure 8: Representative Images of Cells and Threshold Gating of SW837 Cells8. A 
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demonstrates microscopic image with the Marco applied Yen Dark threshold. B Demonstrates 
raw image from microscope at 4x.  
Relative cell confluence was used to evaluate the growth rates of cells seeded in wells with a 
surface area 0.32 cm2 at an absolute cell count of 3x103, 5x103, 1x104, 2x104, 3x104, 5x104, 
and 10x104. Images were taken at 0 hours, 48 hours, 96 hours, and 144 hours. Flasks seeded 
with 3x103 and 5x103 cells had no increase in relative cell confluence from 0 to 144 hours, with 
decreases in cell counts at the 48, and 96-hour mark. The flasks seeded with 1x104, 5x104, and 
10x104 cells had a relative cell count at 144 hours of 3.8, 3.8, and 2.5 times that of 0-hours 
respectively, (see Figure 9.). However, the cell seeding densities that resulted in the greatest 
increase at 144 hours compared to 0-hours was 2x104 and 3x104, with 7.2 and 4.4 times increase 
in relative cell confluence, respectively. These results demonstrate that seeding at 5000 cells 
and below results in an increased cell doubling time and even cell population loss. 
Additionally, seeding above 30,000 cells results in reducing doubling times. Therefore, it was 
concluded that the best seeding density for these cells was around 20,000-30,000 cells. A 
recurring theme for most seeding densities was a slow growth until 96 hours, where rapid 
growth would continue after. The only seeding density that did not display this pattern was 
100,000 cells, which demonstrated constant growth, with population loss after 96 hours. The 
theory to this drop-off after 96 hours was predicted to show the SW837 cells maximum 
population size of around 1700 relative cell confluence. Lastly, another reoccurring theme 




Figure 9: SW837 cells relative cell confluence over 144 hours, recorded from imageJ9 
The different absolute cell seeding densities are as follows: 3E3 = 3x103, 5E3 = 5x103, 1E4 
= 1x104, 2E4 = 2x104, 3E4 = 3x104, 5E4 = 5x104, and 10E4 = 10x104 cells. Note three 
repeats of each data point as three different taken in different location on the flask. 
Measurements were conducted in a 96 well plate with a surface area of 0.32 cm2 
 
Another finding from Figure 9. was that known seeded cell counts at 0-hours did not always 
match the corresponding relative cell confluency. This change was most prevalent in the 5x103 
known cell count, which though it was the second-lowest seeded cell count, had the second-
highest relative cell count. However, it quickly fell back to more expected levels at 48 hours 
and finished as the second-lowest relative cell count. Every other known seeded cell count had 
an expected relative cell count at 0 hours, validating the technique as a potential method of 
measuring relative cell counts from images.  
Further observations also found absolute cell seeding densities of 3x103, 1x104, and 2x104 cells 
at 0-hours had very similar relative cell count values. Similarities indicate that the ImageJ cell 
count technique has a lack of accuracy in lower cell counts. Although this could be due to the 
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low cell density, resulting in highly variable cell densities across the flask. However, ImageJ 
appears to have relatively good differentiation in higher cell counts, potentially due to a more 
consistent cell density spread across the flask.  
3.2 CHARACTERISING SW837 CELL VIABILITY POST-
RADIATION 
A CCK8 assay was used to determine the relative cell viability of SW837 exposed to irradiation 
doses of 0 Gy, 2 Gy, 4 Gy, 6 Gy, 8 Gy, and 14 Gy. Spectrophotometry at 460 nm was used to 
produce absorbance readings, which were used as relative cell viability, with a higher 
absorbance indicating higher cell viability.  
3.2.1 INCUBATION TIMES: 
To determine the optimal post-radiation timepoint to measure cell viability, we performed 
CCK8 measurement after post-radiation incubation times of 24, 38, and 72 hours. 
The flask sets incubated for the two longer durations, 38 and 72 hours, demonstrated much 
higher absorbances throughout the different doses when compared to an incubation time of 24 
hours (See Figure 10.). This was prevalent when analysing the 0 Gy doses of all three 
incubation times. Specifically, the 38-hour incubation time produced a 0 Gy absorbance of 
2.686, and the 72-hours produced an absorbance of 1.888, a difference of 0.798. However, the 
absorbances of 0 Gy for the 24-hour incubation time produced an absorbance of 0.46125, a 
difference of 1.42 compared to the 72-hour incubation time, and 2.2 when compared to the 38-




Figure 10: Relative Cell Viability of SW837 Cells Post-Radiation Dosing10 
Relative counts derived from CCK-8 spectrophotometry at 460nm A) irradiation Exposure 
Event 1 (38-hour incubation time). B) irradiation Exposure Event 2 (24-hour incubation time). 
C) irradiation Exposure Event 3 (72-hour incubation time). Each irradiation dose consists of 
two separate flasks radiated, each with two absorbance readings, all averaged. Error bars 
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from standard deviation of all readings from each irradiation dose. Each reading zeroed to 
media. 
3.2.2 CELL VIABILITY FINDINGS: 
Though not statistically significant due to the lack of repeats, these results demonstrate 
essential information regarding incubation times. Notably, cell growth is slow in the SW837 
cells, requiring a longer incubation time to increase cell viability. This is somewhat evident in 
Figure 10C., which demonstrates that an incubation of 72 hours was the only RE to produce a 
somewhat expected decrease in viability with increasing irradiation dosing.  
3.3 CHARACTERISING SW837 CELL DEATH AND 
APOPTOSIS COUNTS POST-RADIATION: 
Annexin-V stain was used to detect apoptosis in SW837 cells, and Propidium Iodide was used 
to determine total dead SW837 cells in populations detected using flow cytometry. All samples 
mentioned in the methods were stained accordingly and run through the flow cytometer. The 
positive stain controls and unstained were then used to unmix the data during running. 
3.3.1 DILUTION OPTIMIZING: 
First initial flow data was conducted using no pre-dilution of stains as manufactures guidelines 
were followed. Using the full concentration of stains resulted in the fluorescence being too 
intense for our flow cytometer to detect cell death accurately, surpassing the fluorescence limit 
of 1x107. Therefore, a stain titration was conducted to determine the optimal stain dilutions for 
both PI and Annexin-V. Optimal stain dilutions require the fluorescence to be readable by the 
flow cytometry but high enough to produce a high dynamic range.  
The initial dilution titrations for PI and annexin were 1:2, 1:4, 1:8 and 1:16. These dilutions 
resulted in fluorescence intensities that were too high for the flow cytometer. However, it was 
noticeable when running on the flow cytometer that annexin-V, though still too high to read, 
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produced slightly less fluorescence intensity than PI. Following these tests, another dilution 
titration was run using dilutions of 1:25, 1:50, 1:100, and 1:200 for annexin-V and PI. These 
results were within the flow cytometers range; thus, they can be analysed (see Figure 11A.).  
3.3.2 DILUTION FINDINGS: 
Figure 11A. demonstrates a very high specificity for the appropriate stain in the single stain 
positive controls, with very minimal non-specific staining. All samples in the dilution titration 
were heat-killed before staining. Furthermore, the high percentage of staining for both annexin-
V and PI demonstrate the effectiveness at demonstrating cell death and apoptosis. Additionally, 
for all the samples, the percentage of cells positive for annexin-V staining was lower than PI 
staining, which is expected as PI is total dead cells, while Annexin-V is only cells undergoing 
apoptosis. The dilutions tested concluded that a 1 in 200 was best for both, as this gave a high 
percentage of staining while being the most in range of the flow cytometers maximums.  
3.3.3 IRRADIATION FINDINGS: 
The flow data from irradiation exposure events 1 and 2 are presented in (Figure 11B and C.). 
irradiation exposure event one cells were incubated for 38 hours, while event two were 
incubated for 24 hours. Positive single stained controls in RE1 for both annexin-V and PI 
demonstrate, a high specificity and percentage of cells stained with >98% staining for both PI 
and annexin-V. Additionally, with less than 0.6% detectible stain that was not explicitly stained 
for. RE2 demonstrate high cell staining for single stain positive controls, with over 90% for 
both PI and Annexin-V. However, the RE2 positive single stained PI control was not very 
specific for PI only, with 74% of cells positive for Annexin-V, even though it was only stained 
with PI. Flow results for RE3 are not present, as the cell counts in the SET 1 flasks were not 
high enough to accurately record data for flow cytometry. 
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The samples in RE1 demonstrate high amounts of apoptosing cells across all irradiation doses, 
around 20-30%. There is a non-statistical increase in apoptosing cells with increased Gy 
dosing. PI staining and thus, percentage of necrosed cells was low throughout the irradiation 
dosing (<7%). This is an interesting finding, initially demonstrating increased apoptosis post-
radiation exposure in the cells, with limited necrosed cells.  
RE2 demonstrates no changes in the percentage of apoptosing or total dead cells between 
irradiation doses administered. Furthermore, the percentage of cells undergoing apoptosis was 




Figure 11: Percentage of SW837 cells stained with Propidium Iodide and/or Annexin-V 
derived from Flow Cytometry11 Percentage of cells stained positive was derived from 
determining cells of interest followed by determining positive staining. The percentage of 
positive stained cells were then turned into a percentage of total cells of the SW837 population 
to normalize for difference in cell counts. Annexin-V = An, Propidium Iodide = PI. All have a 
PI and A single stain control: PI pos, and An Pos.  A) Demonstrates SW837 cells heat-killed 
and stained with different doses of An and PI. Average cells of interest count was 32905. B) 
Demonstrates SW837 cells radiated with different doses of irradiation as Gray (Gy) compared 
to combined staining of PI and An. Specifically RE1. Average cells of interest count was 51220. 
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C) Demonstrates SW837 cells radiated with different doses of irradiation as Gray (Gy) 
compared to combined staining of PI and An. Specifically RE 2. Average cells of interest count 
was 7781.  
 
3.4 CHARACTERIZATION OF DNA DSB OF IRRADIATED 
SW837 CELLS:  
3.4.1 PROTEIN QUANTIFICATION AND TOTAL PROTEIN NORMALISATION: 
Initially, a BCA assay was conducted to determine protein concentrations for each sample in 
each RE (See Table 5.) Absorbances of samples were then converted into protein 
concentrations of 0.8 or 1.5 ug, depending on RE, in each well of the western blot gel. However, 
protein loading was supposed to be at 20 or 100 ug but was not due to a calculation error. Most 
protein concentrations were high, indicating successful lysis of cells.  
Table 5: BCA Derived Protein Concentration (μg/mL) of SW837 Irradiated cells5 
Sample: RE 1 Gy: Protein(ug/mL): RE 2 Gy: Protein(ug/mL):2 RE 3Gy: Protein(ug/mL):3 
1 0 1650.0 0 925.9 0 1570.0 
2 0 1878.6 0 1630.0 0 1978.4 
3 2 2047.3 2 1270.0 2 1860.0 
4 2 1660.0 2 1603.4 2 1768.4 
5 4 1566.8 4 1648.4 4 2055.0 
6 4 1665.4 4 1504.4 4 1927.5 
7 6 1822.7 6 1596.7 8 1818.4 
8 6 1679.1 6 1360.0 8 2004.2 
9 8 1726.4 8 1470.9 14 1760.0 
10 8 1437.7 8 1401.7 14 1483.4 
 
3.4.1 OPTIMIZING THE EXPRESSION OF Γ-H2AX VIA WESTERN BLOTTING: 
Western Blotting was conducted to detect γ-H2AX as a sign of irradiation induced DNA 
damage in SW837 cells. These methods of detecting irradiation damage were a first in our 
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laboratory and resulted in significant challenges. Therefore, optimising and troubleshooting the 
SDS-PAGE western blot protocol was required.  
RE1 western blot protocol started with the addition of the lysis buffer 30 minutes after 
irradiation. These RE1 samples were used to produce an antibody dilution assay (See Figure 
12.). It was decided to test γ-H2AX antibody dilutions of 1:200 and 1:500 and secondary 
antibody dilutions of 1:2000 and 1:4000. These were derived from manufacturers 
recommended working concentrations. B-actin was used at the manufacturers working 
concentrations. Initial results demonstrate B-actin appearing at roughly 40 kDa, close to its 
actual kDa of 42. This appearance demonstrates that multiple factors were successful: 1) The 
cell lysates successfully released b-actin and ran down the gel. 2) Both the B-actin and 
secondary antibody were able to bind and be detected via the imaging process successfully. 3) 
The ladder successfully ran down, indicating the size of B-actin accurately. And 4) the protein-
loading loaded sufficient amounts of protein to detect B-actin 
What was not successful in the dilution assay was the expression of γ-H2AX throughout all the 
dilutions. Only the 0 Gy and 8 Gy radiated samples were used in the dilution assay, this led to 
running all RE1 samples on a gel. This was done to ensure that the few samples used were not 




Figure 12: SDS-PAGE Western Blot Analysis of γ-H2AX Extracted from Radiated SW837 
cells, Irradiation Exposure 1, Antibody Dilution Optimization 12 
Beta-actin used as protein normalizer. Phospho-Histone γ-H2AX (ser14) Monoclonal Antibody 
as primary antibody, paired with secondary antibody; Goat anti-mouse igG secondary 
antibody. Ladder measuring kDa, range of 10 to 260 kDa. SW837 cells radiated with 0 Gy 
(Lane 1), SW837 cells radiated with 8 Gy (Lane 2). 5% BSA used as blocking buffer, 20% Tris-
glycine gels used. Each well loaded with 30 uL, including 6 uL of Reducing sample buffer lane 
marker. A) Antibody dilutions: Secondary 1 in 2000, Primary 1 in 200. B) Antibody dilutions: 
Secondary 1 in 2000, Primary 1 in 500. C) Antibody dilutions: Secondary 1 in 4000, Primary 
1 in 200. D) Antibody dilutions: Secondary 1 in 4000, Primary 1 in 500. E) Antibody dilutions: 
Secondary 1 in 2000, Primary 1 in 200. E) Antibody dilutions: Secondary 1 in 2000, Beta-
actin. 
3.4.2 WESTERN BLOT IRRADIATION EXPOSURE EVENT 1 FINDINGS: 
RE1 sample run was conducted the same as the dilution run, however, with all the irradiation 
dose samples. The dilutions used are as follows; the secondary antibody dilution of 1:2000, 
and γ-H2AX antibodies at a dilution of 1:200. These dilutions were chosen, as the secondary 
dilution worked with B-actin, and since γ-H2AX was not expressed on the gel, it was safer to 
go for a more concentrated dilution.  
The B-actin banding appeared fainter, with it only showing up at roughly 40 kDa in the 0 Gy 
irradiation samples. Although everything was kept the same as previous, the 8 Gy irradiation 
dose did not demonstrate any B-actin banding. However, it did demonstrate some banding at 
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250 kDa. When analysing the γ-H2AX antibody staining samples, much as in the dilution 
western blot, no expression of γ-H2AX staining was seen (see Figure 13.). γ-H2AX should 
appear around 15 kDa.  
 
Figure 13: SDS-PAGE Western Blot Analysis of γ-H2AX Extracted from Radiated SW837 
cells, Irradiation Exposure 1 13:Beta-actin used as protein normalizer. Ladder measuring kDa, 
range of 10 to 260 kDa. 5% BSA used as blocking buffer, 20% Tris-glycine gels used. Each 
well loaded with 30 uL, including 6 uL of Reducing sample buffer lane marker. A) SW837 cells 
radiated with 0 Gy, 2, 4, 6, 8 Gy (Lane 1-10). Stained 1 in 200 Phospho-Histone γ-H2AX 
(ser14) Monoclonal Antibody as primary antibody, paired with 1 in 4000 secondary antibody; 
Goat anti-mouse igG secondary antibody B) SW837 cells radiated with 0 Gy (lane 1), 8 Gy 
(lane 2). Stained with Beta-actin as primary, with 1 in 4000 secondary antibody; Goat anti-
mouse igG secondary antibody. 
 
3.4.3 CHANGING THE GEL ELECTROPHORESIS RUN TIME AND VOLTAGE, AS 
WELL AS ALTERNATIVE LYSIS ADDITION: 
For RE2 and RE3, it was decided to add the lysis buffer immediately after irradiation. This 
lysis buffer had phosphatase and protease inhibitors added to protect phosphorylated protein. 
Since γ-H2AX is rapidly degraded by protease and phosphatases post-formation from 
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irradiation damage, it is vital to inhibit immediately after irradiations to get consistent yields 
of γ-H2AX.  
Additionally, steps that were made to improve the successes of γ-H2AX in western blot yields 
are as follows. Since γ-H2AX is a considerably small protein at 15 kDa, the gel electrophoresis 
was run at 100 volts for 1 hour, ensuring the protein was not being run off the gel (See Figure 
14.). However, no γ-H2AX or B-actin banding showed in both RE2 and RE3.  
 
Figure 14: Western Blot Analysis of γ-H2AX Extracted from Irradiated SW837 cells14. RE2 
= irradiation exposure event 2. RE3 = irradiation exposure event 3. Beta-actin used as protein 
normalizer. Ladder measuring kDa, range of 10 to 260 kDa. 5% BSA used as blocking buffer, 
20% Tris-glycine gels used. Each well loaded with 30 uL, including 6 uL of Reducing sample 
buffer lane marker. A) SW837 cells radiated with 0 Gy, 2, 4, 8, 14 Gy (Lane 1-10). Stained 1 
in 200 Phospho-Histone γ-H2AX (ser14) Monoclonal Antibody as primary antibody, paired 
with 1 in 4000 secondary antibody; Goat anti-mouse igG secondary antibody B) SW837 cells 
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radiated with 0 Gy (lane 1), 14 Gy (lane 2). Stained with Beta-actin as primary, with 1 in 4000 
secondary antibody; Goat anti-mouse igG secondary antibody. 
3.4.4 COOMASSIE BLUE: 
A Coomassie blue stain was conducted to investigate why no staining of γ-H2AX or B-actin 
occurred in RE2 and RE3. Coomassie blue stain showed non-specific protein used to determine 
if any protein is present and running down the gel (See Figure 15.). RE2 and RE3 Coomassie 
blue assays demonstrated limited protein bands at the 50-70 kDa size range, with no visible 
banding from images around the γ-H2AX size of 15 kDa.   
 
Figure 15: Coomassie Brilliant Blue Staining of SW837 Cell Line Protein make up using 
20% Tris-Glycine Gels15. Ladder measuring kDa, range of 10 to 260 kDa. Each well loaded 
with 30 uL, including 6 uL of Reducing sample buffer lane marker. SW837 cells subjected to 
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different irradiation dosing: 1,2 = 0 Gy, 3,4 = 2 Gy, 5,6 = 4 Gy, 7,8 = 8 Gy, 9,10 = 14 Gy. A) 
SW837 cell irradiation exposure 2. B) SW837 cell irradiation exposure 3. 
3.4.5 WESTERN BLOT OPTIMISING TRIAL 1: 
RE3 samples were used for the optimisation assays; this was due to the improved lysis addition 
timing. The electrophoresis was kept at 100-volts for 1 hour to ensure γ-H2AX was not running 
off. The two changes made are as follows. The power blotter settings were changed from 
standard molecular weight to low molecular weight (25 volts, 1.3 amps for 5 minutes). The 
intention for this was to ensure the small γ-H2AX protein was not running through the blotting 
paper. Additionally, we increased the protein loading from 0.8 ug to 1.5 ug because the 
Coomassie blue gel showed no banding around protein of interest.   
However, both B-actin and γ-H2AX failed to present any banding on the blotting paper (See 
Figure 16.). Therefore, further optimising was needed. 
 
Figure 16: Western Blot Analysis of γ-H2AX Extracted from Radiated SW837 cells RE3 
optimizing trail 1 16. Beta-actin used as protein normalizer. Ladder measuring kDa, range of 
10 to 260 kDa. 5% BSA used as blocking buffer, 20% Tris-glycine gels used. Each well loaded 
with 30 uL, including 6 uL of Reducing sample buffer lane marker. A) SW837 cells radiated 
with 0 Gy, 2, 4, 8, 14 Gy (Lane 1-10). Stained 1 in 200 Phospho-Histone γ-H2AX (ser14) 
Monoclonal Antibody as primary antibody, paired with 1 in 4000 secondary antibody; Goat 
anti-mouse igG secondary antibody B) SW837 cells radiated with 0 Gy (lane 1), 14 Gy (lane 
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2). Stained with Beta-actin as primary, with 1 in 4000 secondary antibody; Goat anti-mouse 
igG secondary antibody. 
3.4.6 WESTERN BLOT OPTIMISING TRIAL 2: 
As before, this optimising trial was conducted using RE3 samples, with all the previous 
changes in trial one consistent with trial two. This was due to the belief that the changes in trial 
one may increase the chance to detect γ-H2AX, as they are primarily involved in increasing 
band strength. Additional changes made in trial 2 are as follows. Firstly, samples in lysis were 
first aggravated with a 28-gauge needle and boiled at 100ºC for 15 minutes. Previous research 
indicated this as a possible way of increasing the availability of γ-H2AX in the lysis suspension. 
Secondly, the use of 3% BCA blocking buffer was used rather than 5%. Specifically, this was 
to further improve staining by reducing the blocking of all staining. Lastly, a reduction in 
washing with TBST between stains was conducted. This also was to try to increase total 
staining to ensure the staining protocol was thorough enough. However, both B-actin and γ-




Figure 17: Western Blot Analysis of γ-H2AX Extracted from Radiated SW837 cells RE3 
optimizing trail 117. TOP = Repeat 1. BOTTOM = Repeat 2. Beta-actin used as protein 
normalizer. Ladder measuring kDa, range of 10 to 260 kDa. 3% BSA used as blocking buffer, 
20% Tris-glycine gels used. Each well loaded with 30 uL, including 6 uL of Reducing sample 
buffer lane marker. A) SW837 cells radiated with 0 Gy, 2, 4, 8, 14 Gy (Lane 1-10). Stained 1 
in 200 Phospho-Histone γ-H2AX (ser14) Monoclonal Antibody as primary antibody, paired 
with 1 in 4000 secondary antibody; Goat anti-mouse igG secondary antibody B) SW837 cells 
radiated with 0 Gy (lane 1), 14 Gy (lane 2). Stained with Beta-actin as primary, with 1 in 4000 
secondary antibody; Goat anti-mouse igG secondary antibody. 
 
3.5 MIRNA EXPRESSION CHANGES TO IRRADIATION 
EXPOSURE IN SW837 CELLS: 
Analysis of miRNA expression post irradiation was used to profile miRNA that have 
previously been identified as being correlated with chemoradiation response in patients, to 
determine if they are differentially expressed in rectal cancer cells post-radiation. This was 
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conducted by rt-qPCR to quantify the miRNA in each sample. Samples after incubation were 
lifted and stored in a lysis buffer. An RNA extraction was then performed, using nanodrop to 
determine the quality and quantity of RNA.  
3.5.1 RNA QUANTIFICATION AND QUALITY ANALYSIS: 
The nanodrop results for RE1 demonstrate mostly high RNA yields, except from sample 3 and 
good 260/280 ratios (1.91-2.21). The RE2 nanodrop results are similar to RE1, with average 
RNA concentrations of RE1 at 22.03 ng/uL and 27.63 ng/uL for RE2. Additionally, 260/280 
ratios are reasonably similar. For RE3, there is a slightly different story. The 260/280 ratios are 
lower (1.14-1.48), indicating reduced nucleic acid purity. Additionally, RNA yields are 
considerably lower on average, with only 16.47 ng/uL (See Table 6) These results for RE3 
may result from decreased cell counts in SET 3, as was seen in the flow cytometry assays.  










260/280: 260/230: [RNA] 
(ng/uL): 
260/280: 260/230: [RNA] 
(ng/uL): 
260/280: 260/230: 
1 27.9 1.99 0.17 22.7 2.08 0.16 27.6 1.48 0.14 
2 29.9 2.08 0.07 22.3 1.9 0.62 29.6 1.47 0.18 
3 5.8 1.91 0.1 30.4 1.67 0.16 7.3 1.37 0.16 
4 34.7 1.99 0.16 31.2 1.72 0.25 8.4 1.33 0.14 
5 18.8 2.21 0.05 17.4 2.11 0.94 9.5 1.42 0.11 
6 36.1 2.06 0.08 23.6 1.82 0.36 12.4 1.38 0.14 
7 18.2 2.05 0.09 14.8 2.09 2.83 4 1.27 0.26 
8 10.8 2.02 0.08 18 1.68 0.12 19 1.14 0.16 
9 18.1 2.18 0.08 67.5 1.51 0.24 28.9 1.36 0.13 
10 20 2.06 0.05 28.4 1.71 0.23 18 1.38 0.16 
Total 22.03 2.055 0.093 27.63 1.829 0.591 16.47 1.36 0.158 
 
3.5.2 REAL-TIME QUANTITATIVE PCR: 
After RNA isolation, cDNA synthesis, followed by amplification, was performed. This was to 
increase miRNA concentrations enough to allow for RT-qPCR to function. Cq values were 
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recorded from RT-qPCR. Cq values indicate the number of cycles needed for the sample 
reaction curve to reach the threshold set previously. With this, the Cq maximum value was set 
to 35, indicating the cut off threshold for technical detection of product. This criterion resulted 
in the exclusion of RE1 and RE3 RT-qPCR results. More specifically, RE1 has significantly 
high Cq values across most miRNA, while RE2 had too many missing results, likely a cause 
of the low RNA concentrations (See Table 7.). Therefore, the only RT-qPCR results left to 
analyse were from RE2. 





















0 a35.50 35.09     37.93 35.61     32.53 32.28 38.17 38.07 
0 34.47 34.30     30.73 30.62 38.32 35.82 32.43 32.13 35.16 35.37 
2 28.51 28.25 29.10 29.07 27.03 26.91 31.66 31.52 27.01 26.86 27.56 27.52 
2 26.02 27.41 27.24 27.24 25.87 25.94 29.34 29.42 25.32 25.14 25.35 25.51 
4 25.15 25.90 26.52 26.45 24.28 24.39 28.45 28.18 23.43 23.39 24.18 24.31 
4 25.98 25.88 26.69 26.59 24.94 25.03 28.68 28.39 25.04 25.42 25.58 25.61 
8 24.29 24.17 24.99 25.03 23.29 23.40 27.45 26.88 22.32 22.56 23.70 23.82 
8 26.54 26.52 27.59 27.62 25.50 25.64 30.55 30.68 26.02 25.18 26.16 26.13 
14 29.81 29.20 30.26 30.03 28.06 28.05 35.90 35.53 28.58 28.58 28.73 29.23 
14 26.17 25.58 26.84 26.98 25.69 25.35 31.16 29.80 24.42 24.44 26.07 25.87 
 
aRed indicates cut out row 
bIndicates miRNA 
 
3.5.3 RE2 REAL-TIME PCR RESULTS: 
RE2 Cq values were then converted to fold change of the lowest irradiation dosing (see 
methods for more details), plotted in (Figure 18.). The lowest irradiation dose for R2 was 2 
Gy, as the Cq values for 0 Gy dosing were too high or did not read. Although this means 
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comparisons to no irradiation exposure cannot be made, a irradiation dose-response can still be 
gauged.  
Since the number of repeated RE was one, and each irradiation dose was only done in duplicate, 
no statistical data or validation was produced. However, there are differences, but due to the 
n=1, the ability to interrupt this was limited, but still may indicate where further research would 
be most interesting. MiRNA-25-3p and miRNA-26b-5p demonstrate no increasing or 
decreasing expression changes across the irradiation doses. However, the differences in 
duplicates and lack of repeats indicate not enough evidence to state a trend. MiRNA-23a-3p 
shows an increase in expression as irradiation dosing is increased. Additionally, miRNA-185-
5p demonstrates decrease in expression when irradiation dosing is increased. These two 
differences were not able to have statistical testing applied, but they could demonstrate some 




Figure 18: Irradiation Event 2 miRNA Fold Change Expression to 2 Gy Irradiation 
Exposure in SW837 Cells via real-time PCR18. Different irradiation doses to SW837 cells 
were normalized to the geometric mean of miRNA425, and miRNA335. These irradiation doses 
Cq values were converted to fold change difference to the lowest Gy dose, which was 2 Gy. A 
Cq value above 35 was not analysed due to being too high. Each repeat of the irradiation doses 
was from the two flasks radiated at the same dose. Additionally, two repeats of every sample 




CHAPTER 4: DISCUSSION: 
4.1 CLINICAL IMPORTANCE: 
Many rectal cancers do not respond to radiotherapy. The lack of response in people affected by 
these conditions can be very damaging, due to more effective alternative treatments that could 
have been used instead, and the significant burden on their quality-of-life that radiotherapy can 
induce. Therefore, it was important in this study to lay the foundation to researching miRNA 
mechanistic role in radioresistance. Herein, we discuss optimised assays for detecting 
irradiation damage and irradiation-induced cell death. Furthermore, the study inspects how the 
change of miRNA expression to irradiation exposure can be a viable way of determining the 
role of miRNA in radioresistance and radiosensitisaton. 
Cellular viability, cell death, and cells undergoing apoptosis were used to analyse SW837 cells 
subjected to either increasing doses of irradiation or none at all. This was to validate that the 
SW837 cells were being affected by irradiation, as a known cellular response to irradiation is 
the decrease in cellular viability, an increase in cellular death, and apoptosis. A study by Murad 
et al. 2018 found that when the T98G human glioblastoma cell line was irradiated with 10 Gy, 
cell viability dropped to 73.61% of the original when irradiated, while cells undergoing 
apoptosis increased from 9.63% (no irradiation) to 40.16% (88). Additionally, a similar 
decrease in cell survival was found with the Caco-2 colon cell line when exposed to 10 Gy of 
irradiation in a study by Guardamagna et al. 2021 (89).  
Ionising irradiation can cause cellular death by directly damaging DSB. Therefore, it is 
important to gauge the prevalence of DSB in our study to determine how irradiation effects 
rectal cancer cells. More in-depth, if DSB occurrence is high, but cell viability is also high, this 
may indicate a high degree of DNA repair and a potential mechanism of radioresistance.  
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As mentioned previously, this study used the SW837, Homosapien, epithelial adenocarcinoma, 
stage 4 rectal cancer cell line. When studies use cell lines to study CRC, they usually determine 
the cell line based on subtype gene expression signatures of interest to their study, such as in 
Ronen et al. 2019 (90). Different gene expression subtypes of CRC are significant to study as 
they are predictive of treatment response and prognosis. Subsequently, this has led to the 
frequent use of colon cancer-derived cell lines to study all CRCs. A review by Ronen et al. 
2019 found that colon cancer cell lines SW480 and SW620 were good predictors of how drugs 
respond to CRC tumours. Additionally, Hoffmann et al. 2015 found that the colon cancer cell 
lines Caco-2, DLD-1, COLO-205, HT-29, and HCT-116 successfully mimicked the tumour 
environment for the study of drug response in CRC (91). Overall, a significant amount of CRC 
research is conducted using only colon cancer cell lines, disregarding rectal cancer cell lines.  
The problem with only using colon cancer cells to study CRC is that the location of the tumour 
can significantly impact what treatments will be chosen. This is evident with CRC located in 
the rectum. Due to the less mobile location of rectal cancers than other colorectal sites, 
radiotherapy is often used as a neo-adjuvant treatment before curative-intent surgery (17). 
Additionally, the differences in molecular make up between colon and rectal cancers can 
influence how the tumours behave to different treatments. Therefore, it is more relevant to 
study a rectal cell line when studying rectal cancer irradiation treatment. Thus, this study 
decided to use the SW837 rectal cancer cell line. 
4.2 KEY FINDINGS: 
There were two main aims for this current study: 1) To characterise the effects irradiation has 
on a rectal cancer cell line by assessing the cell viability changes and γ-H2AX expression to 
increasing doses of irradiation. 2) Characterising the expression changes of miRNA within the 
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rectal cancer cell line when subjected to a differing irradiation dose. Specifically, to determine 
miRNA that could be used to predict the radiosensitivity of rectal cancer cells.  
The key findings regarding aim one include:  
1) There was some non-statistically backed decrease in cell viability with increasing irradiation 
doses in SW837 cells. However, optimizing irradiation protocols and cell viability assays 
should be done to improve differentiation of cell viability. 
 2) Longer incubation times after irradiation present greater differences of cell viability 
between irradiation doses. Therefore, it was hypothesised that longer incubation times might 
give the cells more time to die and proliferate, furthering the differences in cell viability 
between irradiation doses to detectable levels.  
3) Increased irradiation dosing did not show increased cell death or apoptosis when using flow 
cytometry. However, this may change with increasing incubation times.  
4) The assays chosen to analyse γ-H2AX expression as an indicator of irradiation damage may 
need more optimising. Alternatively, different assays to detect γ-H2AX may be considered. 
The key findings regarding aim two include:  
5) No statistically relevant RT-qPCR data was produced due to only one repeat being collected, 
due to the complete failure of two repeats and uncontrollable events reducing the ability to 
gather more data.  
6) miRNA-185-5p showed a numerical decrease in expression when compared to increasing 
irradiation dosing. Conversely, miRNA-23a-3p showed a non-statistically significant increase 
in expression when compared to increasing irradiation dosing.  
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4.3 OBJECTIVE 1: CHARACTERISATION CELLULAR 
RESPONSE TO IRRADIATION:  
4.3.1 CELL VIABILITY, DEATH, AND APOPTOSIS FINDINGS: 
CCK8 was used to determine the cell viability of SW837 cells which underwent irradiation at 
different doses. The main difference between the different RE were the incubation times as 
follows: RE1 was incubated for 38-hours, RE2 for 24-hours, and RE3 for 72-hours. Cellular 
death and apoptosis were determined using PI and annexin-V staining respectively, recorded 
with a flow cytometer. 
A major consideration to the incubation times was the slow doubling time of the SW837 cells. 
SW837 cells have a doubling time of 169-hours, which is considerably longer than some colon 
cancer cell lines, such as the SW480 cell line, which has a doubling time of 60-hours (92). This 
long doubling time was evident in this study, with a doubling time of around 96 hours when 
seeded at 5x104 cells in a well with a surface area of 0.32 cm2 (See Figure 9.).  Subsequently, 
this resulted in prolonged periods between irradiation events for the cells to be confluent 
enough for irradiation. Furthermore, incubation times post-radiation was needed to be longer 
than expected, resulting in additional optimising steps. However, the SW837 cellular doubling 
time assay conducted in Figure 9. allowed us to determine the best confluency to seed at for 
the fastest doubling time. 
Incubation times varied due to previous studies finding the greatest cellular response 
differences between irradiation doses varied depending on the doubling time of the specific 
cell line. For example, a study by Guardamagna et al. 2021 found irradiated Caco-2 cells, 
demonstrated the greatest cell viability difference between irradiation doses occurred 48 hours 
post-radiation, compared to 6, and 24 hours. 48 hours was considered optimal as it allowed 
cells to complete an entire cell cycle. A cell cycle can allow the cell to respond to irradiation, 
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differentiating into senescence, death, and repair. Additionally, Murad et al. 2018 found that 
when dosing T98G cells with 10 Gy, cells did not enter the apoptotic phase until 72 hours post-
radiation. 
Since cellular response differences were greatest when a full cell cycle occurred, it was 
theorised that a longer incubation time would be more suitable for the SW837 cells. This was 
concluded from the fact that it was found that the SW837 cells had a 90-hour cell cycle time 
(See Figure 9.). Therefore, according to the literature, the highest tested incubation time of 72 
hours should result in the more discernible differences. Test times longer than 72 hours was 
avoided as it was recorded that at 96 hours post-radiation, cell viability increases (88). 
4.3.2 38-HOUR INCUBATION TIME: 
For RE1, the range of irradiation dosing used was 0, 2, 4, 6, and 8 Gy. Neither cell viability 
nor cell death changed between 0 and 8 Gy (See Figure 10A and Figure 11B.). While 
apoptosis showed a 7% increase from 0 Gy to 8 Gy, this could not be backed by statistical 
analysis due to 1 repeat. Furthermore, the heat killed positive cells showed significant cell death 
and apoptosis, rejecting irradiation exposure as a significant source of cell death and apoptosis 
in SW837 cells with a 38-hour incubation period. 
4.3.3 24-HOUR INCUBATION TIME: 
For RE2, as well as the changed incubation time, irradiation dose was increased to 14 Gy. This 
was to ensure irradiation dosing was not the limiting factor, as some cancer cell lines can be 
more radioresistant than others, as evident in a study by Murad et al. 2018 which found T98G 
cells did not respond to irradiation until 10 Gy doses were used. However, this did not change 
the outcome, with no difference in cellular viability, apoptosis, or cell death between 0 and 14 
Gy irradiation (See Figure 10B and Figure 11C.). Therefore, rejects irradiation of SW837 
cells as a source of cell death and apoptosis with a 24-hour incubation time.   
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4.3.4 72-HOUR INCUBATION TIME: 
RE3 findings indicate that viability decreased with increasing irradiation doses, with 14 Gy 
presenting a 30% decrease in cell viability compared to 0 Gy of irradiation. This was the most 
discernible difference of any of the incubation times (See Figure 10C.). However, no statistical 
tests could be conducted due to the lack of repeats. This may demonstrate that incubating 
SW837 cells for a longer time post-irradiation could allow for a full cell-cycle to procced, 
increasing the discernible differences between irradiation doses.  
However, cell death and apoptosis could not be determined for RE3, as the flasks of Set 1 had 
too few cells to accurately record with flow cytometry. These assays should be replicated to 
see if the incubation time benefits translated to the cell death and apoptosis assays. 
4.3.5 CELL-CYCLE CONSIDERATIONS: 
Due to the importance of the competition of a cell-cycle post-irradiation to be able to 
demonstrate a discernible cellular response, the specific investigation of the cell-cycle in 
SW837 cells post-irradiation could complement or replace current cellular response assays. 
Understanding the cell cycle can give insight into whether the irradiation damage is leading 
cells into senescence rather than cellular death. This could allow insight into the mechanisms 
of radioresistance in SW837 cells. 
The FxCycle violet stain paired with an EdU marker detected via flow cytometry can be used 
to determine the G1, G2-M, and S- cell cycle phases (89). This is because the FxCycle violet 
stain binds to DNA; thus, its fluorescence is correlated to the amount of DNA in each cell, 
while the EdU fluorescence is correlated to cells undergoing S-phase (93;94). Therefore, the 
cell cycle can be determined using flow cytometry via the following: Cells undergoing the G1-
phase would demonstrate low DNA content and no EdU staining. Cells underlying the G2-
73 
 
phase would have double the G1 DNA content and no EdU staining. Cells undergoing S-phase 
DNA replication would further increase the DNA content and positive EdU staining (89).  
4.3.6 FUTURE ASSAY CONSIDERATIONS: 
In RE3 Set 1 flasks, few amounts of cells were lifted and thus, flow cytometry could not record 
cell death and apoptosis data accurately. This could be because if the cells are dying, they may 
be lifting into the media prior to manual lifting. Due to the currently protocol removing the 
media before lifting, the cells that prematurely lifted are discarded, limiting our collection of 
dead and apoptosing cells. Therefore, it is recommended that media is collected, centrifuged, 
and pellet added to the lifted cell pellet.  
4.3.7 OVERALL LOW CELLULAR RESPONSE TO IRRADIATION IN SW837 
CELLS.  
One common result across these assays is the lack of cell viability change, cell death, and 
apoptotic cells when SW837 cells are exposed to 14 Gy of irradiation compared to no 
irradiation. Only the 72-hour incubation cell viability tests displayed a significant decrease in 
cell viability due to increasing irradiation doses. Additionally, the percentage of irradiated 
SW837 cells that were apoptotic did not differ to non-irradiated SW837 cells with 24 or 38-
hour incubation times. It was found by Murad et al. 2018, that irradiated T98G cancer cells had 
a 38% increase in apoptotic cells when irradiated. This disparity in our results compared to the 
literature could be caused by two reasons: 1) The SW837 cells are radioresistant. 2) The cells 
used in the study by Murad et al. 2018 were incubated for 72-hours before analysing, and with 
our 72-hour data missing we were not able to collect accurate data of when cells died. 
Therefore, it is recommended to reattempt the 72-hour incubation time apoptosis assay with 




4.3.8 ADDITIONAL CELL LINE IMPACT ON THE CELLULAR RESPONSE TO 
IRRADIATION: 
Another challenge this study faced when working with SW837 cells was keeping them growing 
at a healthy pace. Often cell cultures would slow rapidly in growth, accompanied by a change 
to microscopic morphology, becoming rounded and smaller. Commonly known reasons as to 
how an immortalised cancer cell line can reduce in growth rate include the following: Cells 
being passaged too many times and microbial contamination, as well as poor quality media, 
serum, and buffers (95). This cell culture behaviour could affect the results of the cell viability 
assays, with the potential to have different irradiation events grow at different rates, resulting 
in difficulty in comparing between irradiation events. 
4.4 Γ-H2AX PRESENCE AS AN INDICATOR OF 
IRRADIATION-INDUCED DNA DAMAGE: 
When a DSB occurs, DNA pathways known as the DNA damage response (DDR) are 
responsible for detecting, signalling initiation, and repairing the DSB (96). One of the first 
events in the DDR pathway is the phosphorylation of H2AX to produce γ-H2AX. Γ-H2AX is 
believed to be crucial to initiating the DDR, as its chromatin modification properties allow it 
to increase DNA accessibility, allowing for further DDR components to access the DNA (97). 
Therefore, γ-H2AX is considered one of the first detectable indicators of DSB (96).  
4.4.1 WESTERN BLOT RESULTS: 
As mentioned in the results, all western blot attempts failed to present γ-H2AX banding in any 
samples or repeats. Additionally, b-actin failed to present banding for all western blots except 
for RE1 0 Gy and 8 Gy exposed cells. Since b-actin failed to show for all, it is likely that the 
lack of staining is due to a technical issue that we did not have time to fully resolve. 
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B-actin is commonly used as a positive control that can normalise protein concentration to 
reduce protein loading errors. This is possible as b-actin protein expression in cells that are the 
same is constant and well expressed. At 42 kDa, it is well in the range of most western blot 
detectable molecular weights and is easy to stain for, with strong, resulting banding. Since b-
actin demonstrated banding in RE1, but not RE2 or RE3, something altered its expression. 
Herein, we explore known changes and potential causes to reduce b-actins presence in RE2 
and 3. 
The first major difference was the time point at which the lysis buffer was added (See Figure 
7.). This change was in response to γ-H2AX not showing in RE1, as it was believed the delayed 
lysis addition was too long. Since γ-H2AX is degraded back to H2AX via phosphatases after 
DSB, the lysis buffer had phosphatase inhibitors added to preserve γ-H2AX. Therefore, it was 
believed that adding the phosphatase inhibitors 30 minutes after irradiation may be too long to 
reduce γ-H2AX breakdown, resulting in the lack of RE1 γ-H2AX banding. However, b-actin 
is not majorly sensitive to the timing of cellular lysis; and thus, it could not be concluded as 
the reason for b-actin failing to show.  
Another major difference was setting the gel electrophoresis to 100 volts for 1 hour (See Figure 
7.). Previously in RE1, gel electrophoresis was run at 120 volts for 1 hour and 20 minutes. 
However, it was changed because it was theorized that the small protein size of γ-H2AX (15 
kDa) may have been run off the RE1 western blots. Therefore, to ensure we could capture it on 
the gel, the electrophoresis was run well short of the end of the gel. Additionally, no 
hypothesises could be made which explained this as a cause of decreased b-actin banding.  
The final difference was that the primary and secondary antibodies were made fresh for RE1, 
while for RE2 and RE3 they reused the antibodies from RE1. These reused antibodies were 
stored at 4⁰C for no more than two weeks before being used. Additionally, the greatest risk to 
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storing antibodies is if the dilution medium can facilitate microbial growth, such as skim milk 
(99). However, we used TBST to dilute in, which has a low chance to facilitate microbial 
growth. Furthermore, it was concluded by Boonrod et al. 2010, that reusing antibodies for 
western blot did not significantly reduce signal intensity over four uses. 
4.4.2 TROUBLESHOOTING WESTERN BLOTS: 
Since it could not be concluded why b-actin was not present in RE2 and RE3, troubleshooting 
was conducted (See Figure 7.). A Coomassie blue demonstrated significant non-specific 
protein running through the gel around 60-70 kDa. However, other proteins at different 
molecular weights were present throughout the gel, producing faint banding. The faint banding 
may have resulted from the imaging method of using photography rather than a dedicated 
imaging machine or more likely, due to insufficient protein loading. Future Coomassie blue 
gels may benefit from using a dedicated imaging machine. Subsequently, it was concluded at 
least some protein was running down the gel in RE2 and RE3. Therefore, b-actin should have 
been stained with at least minimal banding.  
The power blotter settings were changed from a broad range molecular weight to low molecular 
weight (See Figure 7.). This was to ensure the medium to low molecular weight proteins b-
actin and γ-H2AX were not being pushed through the blotting paper. Additionally, an increase 
from 20 ug/ml to 100 ug/ml of protein in each ensured enough protein was loaded. However, 
complications with protein loading were found and are discussed later. These initial changes 
resulted in no protein banding (See Figure 16.). 
Another optimizing step was by agitating and boiling the protein before loading. Since γ-H2AX 
is a histone and is part of chromatin during the DDR signalling pathway (97), it is often difficult 
to liberate it to be stained. Therefore, previous researchers have found that shearing the protein 
lysate with a 28g needle and boiling for 15 minutes can increase the liberation of γ-H2AX from 
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chromatin. However, upon further research, simply shearing and boiling may not be adequate 
to dissolve histones. A review by Kurien & Scofield 2012 found that histones may need 6-8 M 
urea of a non-ionic detergent added prior to loading to dissolve (100). Therefore, this should 
be conducted in future assays to ensure γ-H2AX will be available for staining.  Secondly, a 
decreased concentrated blocking buffer and the number of washes was reduced to increase the 
blotting paper's staining. However, these changes resulted in no protein banding (See Figure 
17.).  
4.4.3 PROTEIN LOADING PROBLEMS: 
Upon further investigation of the BCA derived protein dilution calculations, errors were 
observed. Specifically, rather than loading 20 ug of protein per well, 0.8 ug was added. When 
loading 100 ug of protein per well, 1.5 ug of protein was added per well. However, a study by 
Murphy & Lamb 2013 found that loading wells with 1-3 ug of protein provided sufficient 
banding, especially for lowly expressed proteins (101). Since our results demonstrated no 
banding in RE2 and RE3, low protein loading may not be the sole cause of no banding. 
Furthermore, since RE1 had protein loaded in quantities of 0.8 ug, and demonstrated significant 
b-actin banding, low protein loading as a conclusion of no binding is likely not a complete 
picture. It could be deduced that increasing the protein loading per well should be the next step 
in optimising these western blots.  
4.4.4 OTHER REASONS THAT COULD CAUSE IT AND FUTURE STEPS: 
The first potential reason b-actin failed to show for RE2 and RE3 could be the b-actin antibody 
may not be functioning. Thus, other housekeepers, such as GAPDH and α-tubulin (101) should 
be tested. Furthering this, using the b-actin antibody on other cell line protein samples that have 
been shown in our department could express b-actin.  
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The second theory as to the lone expression of b-actin in RE1 was due to contamination. Rather 
than b-actin being stained for, contamination may have been around 40 kDa, similar to b-actin. 
Additionally, after cell media was removed, a wash with PBS was conducted before being 
removed and replaced with lysis mixture. A review by Kurien & Scofield 2012 found that PBS 
not being sufficiently removed from cell culture prior to cell lysis can cause salt contamination. 
Therefore, future assays should ensure PBS is removed.  
As mentioned previously, the histone γ-H2AX may not be becoming dissolved due to 
inadequate shearing. High concentrations of unsheared proteins can increase the viscosity of 
the crude cell extract (100). Therefore, the addition of detergents and agitating with a needle 
as mentioned above, as well as the addition of Benzonase®, can reduce viscosity, increasing 
protein availability for staining (100). 
An additional area of potential failure of western blots is the chemiluminescence substrate used 
to image the banding. As per the laboratory protocol for western blotting, we stained the blots 
in 2 mL of the peroxide solution mixed with 2 mL of the Luminol solution in 6 mL of water. 
However, upon revision of the manufacturer's protocol, peroxide and luminol solutions should 
be used in a 1:1 ratio with no water. Therefore, the lab protocol may result in too diluted 
concentrations to effectively stain; thus, a 1:1 ratio of reagents should be used for future western 
blot assays. 
4.5 OBJECTIVE 2: MIRNA AS A BIOMARKER OF 
IRRADIATION RESPONSE: 
Quantification cycle (Cq) values derived from RT-qPCR demonstrate the number of PCR 
cycles required for the miRNA expression reaction curve to interest the set threshold (102). Cq 
values above 35 were cut off. Samples with many Cq values above 35 also had many failed 
PCR amplifications, indicating the Cq value as a relevant cut-off. 
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4.5.1 IMPORTANCE OF CHARACTERISING MIRNA IRRADIATION RESPONSE: 
It is documented that specific miRNA has been linked to promoting radiotherapy resistance in 
cancer (103; 104). Due to their endogenous gene regulatory properties, dysregulation of 
miRNA can result in decreased or increased gene expression, leading to tumorigenesis (42-45). 
Therefore, the miRNA expression of certain cancers could indicate how the tumour would 
respond to radiotherapy.  
miRNA expression in response to irradiation may give us an idea about how genetic pathways 
are affected by irradiation exposure, and whether this is liked to radio-induced resistance. 
Specifically, it is theorised that if the miRNA expression increases in response to increasing 
irradiation doses, then that miRNA may provide SW837 cells with a radioresistant effect. This 
is believed because cells with a naturally greater expression of that miRNA will be less likely 
to die from irradiation due to the miRNA radioresistant effect. Thus, during the incubation 
period, the cells that survived irradiation proliferate, producing a population stemming from 
the cells that survived, and thus, a greater radioresistant miRNA expression. This theory stems 
from heterogeneity within cancer cell line cultures (105). Due to increased mutation rates and 
chromosomal instability of cancer cells, like cancer cells in tumours, cell line cultures produce 
many genetically different subtypes (50; 105).  
4.5.2 MIRNA QUANTIFICATION RESULTS: 
RE1 and RE3 RT-qPCR results were excluded from analysis as too many results were missing 
or the Cq values were above 35. RE3 was expected to perform poorly as the flow cytometry 
results indicated that Set 1 flasks had low cell counts post-irradiation. However, the reason 
RE1 performed poorly could not be determined. Therefore, RE2 was the only event analysed; 






The results from miRNA-185-5p expression in SW837 cells when subjected to irradiation in 
this study show patterns that mimic the radiosensitisation properties found in previous 
literature. These patterns demonstrated a decreased expression of miRNA-185-5p with 
increasing irradiation doses (See Figure 18). Using the above theory, this decrease in 
expression may mean miRNA-185-5p is causing SW837 cells to be more radiosensitive. This 
is similar to previous studies, such as found in Afshar et al. 2018. However, the correlation 
found in this study could not have statistical analysis applied, as it only included one repeat. 
However, this result indicates an important area of future research.  
In addition to getting more repeats to statistically back the correlation, further testing will need 
to be done to conclude miRNA-185-5p radiosensitivity properties, as mentioned above. 
However, if found to cause radiosensitivity in SW837 cells, it is applicable to potentially be 
used to determine how a tumour may respond to radiotherapy, and thus, should be further 
researched.  
4.5.4 MIRNA-23A-3P: 
This study found a slight pattern of increasing miRNA-23a-2p expression being linked to 
increasing irradiation dosing (See Figure 18). Using the miRNA expression theory above, this 
demonstrates a potential for miRNA-23a-3p to convey irradiation resistance in SW837 cells. 
This result is difficult to link to research, as much of the research is conflicting with miRNA-
23a-2p. With miRNA-23a-3p inducing radiosensitivity in NPC cells, it was also found to 
increase chemoresistance (77; 75). However, no statistical analysis could be made due to the 
lack of repeats, so it is only speculation until further research. However, this indicates potential 
for future research into its use as a biomarker. 
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Furthering this study, miRNA-23a-3p should have more repeats of miRNA expression in 
response to irradiation dosing to validate the results seen here. Additionally, miRNA mimics 
and inhibitors paired with cell viability and death assays should be conducted to determine 
further how its expression is linked with irradiation response in SW837 cells. This may lead to 
miRNA-23a-3p being used as a potential biomarker of irradiation response in rectal tumours.  
4.5.5 MIRNA-26B-5P AND MIRNA-25-3P: 
Although no patterns were seen in relation to miRNA expression and irradiation dose for 
miRNA-26b-5p and miRNA-25-3p, these cannot be ruled out for future study due to the lack 
of repeats (See Figure 18). Specifically, since miRNA-26b-5p has been associated with CRC 
radiotherapy response, and miRNA-25-3p has been associated with CRC prognosis, both 
should not be ruled out from future study (82; 84). 
 4.5.6 ADDITIONAL ASSAYS NEEDED TO VALIDATE MIRNA 
RADIORESISTANCE/SENSITIVE PROPERTIES: 
A study by Liamina et al.2017 used a similar method of determining miRNAs role in irradiation 
resistance (106). They conducted miRNA screening of miRNA expression 1, 4, and 24 hours 
after irradiation in either irradiation-resistant or sensitive cell lines. This allowed for the 
determination of miRNA important to irradiation resistance. Most studies that use a similar 
method as above also incorporate other assays to validate and understand miRNAs role in 
irradiation resistance. These should be explored and used in future assays about the miRNA 
panel of interest effect on radiosensitivity in SW837 cells.  
One additional assay that could be used to validate miRNA role in radioresistance is by using 
a radioresistant cell line (107). An SW837 radioresistant cell line can be produced, and miRNA 
expression between it and wildtype SW837 cell line can be analysed. This was conducted 
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studies by Pedroza-Torres et al.2018, and Liamina et al. 2017 which found specific miRNA 
expression change between a radioresistant cell line and a wildtype cell line.  
Another method to further understand the miRNA role in irradiation resistance is to use specific 
miRNA inhibitors and mimics. These mimics and inhibitors can be specific to a particular 
miRNA and artificially increase or decrease the miRNA expression and function within a cell 
(108). This is a standard method of determining how a specific miRNA's increase or decrease 
affects certain cellular properties, such as irradiation resistance. It has been used for this 
application in studies by Pedroza-Torres et al. 2018 and Ors-Kumoglu et al. 2019 (109).  
The addition of these assays could allow us to confirm miRNA that are correlated with 
irradiation resistance and sensitisation. Additionally, allow us to determine the pathways in 
which they act to regulate such functions. This information can lead to additional research into 
using the miRNA as a biomarker of radiotherapy success.  
4.6 SIGNIFICANCE OF FINDINGS 
This study explored the cellular characteristics and miRNA response to irradiation in the under-
researched SW837 rectal cancer cell line. Neo-adjuvant radiotherapy is more commonly used 
in rectal cancers than in any other CRC site and thus, it is pivotal to use a rectal cell line. 
However, most CRC research is conducted with colon cancer cell lines. Therefore, this study 
ensures the use of a rectal cancer cell line when researching irradiation.  
The SW837 cell line and irradiation have not been extensively researched in our lab. Therefore, 
there is a great deal of importance to develop effective assays to determine cellular viability, 
death, and apoptosis.  Although no statistical testing was conducted on cellular viability, death, 
and apoptosis, interesting results emerged that can be utilised in future research. Firstly, it was 
found that to get the greatest discernible difference between cellular responses in response to 
irradiation, an incubation time the length of the doubling time was needed. The SW837 cells 
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had a doubling time of around 90-hours, therefore, an incubation of 72 hours was chosen as the 
minimal effective incubation time. Secondly, it was theorised that cells that were dying and 
apoptotic may be lifting during the incubation time. Therefore, we concluded that to accurately 
capture dead and apoptosing cells, collecting the cells from the media was necessary.  
miRNA-185-5p and miRNA-23a-3p expression demonstrated a non-statistically tested 
difference when SW837 cells were exposed to irradiation. This could indicate potential areas 
for future research into miRNA influence in irradiation resistance. However, miRNA-26b-5p, 
and miRNA-25-3p cannot be ruled out from future research, as the lack of repeats means that 
no definitive conclusions could be made. 
4.7 OVERALL STRENGTHS AND LIMITATIONS OF THE 
STUDY 
This study was limited by an inability to conducted repeats for all assays. The three repeats that 
were conducted could not be compiled as they were used for optimising and thus, had many 
differences between them. It was planned to determine the optimal RE protocol, from which 
many repeats would be produced. However, due to unforeseen circumstances, additional 
optimising and repeats could not be conducted. Ergo, all results presented were demonstrating 
potential patterns rather than statistically backed correlations. Furthermore, increasing the 
incubation times from 72 hours should have been conducted to determine the best time to 
determine differences in cell viability. However, there was no time to conduct these. 
Additionally, western blotting was unable to produce any banding of γ-H2AX and limited 
banding of β-actin. Optimising was attempted; however, when protein loading errors were 
discovered to be the likely cause, further optimisation could not be conducted to confirm this 
due to the timing. Additionally, limitations of the supply of antibodies due to shipment closures 
in our lab meant optimising was further limited. 
84 
 
miRNA analysis took considerable time to optimise the dilutions of the antibodies. Therefore, 
limited repeats could be conducted. Additionally, RE1 and RE3 failed to yield miRNA RT-
qPCR results, due to high Cq values and failures to run. Therefore, this limited the repeats to 
only one, making miRNA expression correlations underpowered and with no statistical 
backing. 
However, this study did provide vital information regarding the most effective methods of 
detecting post-irradiation cell viability, cell death, and apoptosis. Additionally, it demonstrated 
a need to ensure protein loading was accurate for western blotting. Furthermore, it highlighted 
potential miRNA of interest to conduct further research regarding miRNA expression in 
response to irradiation. 
4.8 FUTURE DIRECTIONS: 
Repeating the optimised protocol of RE3 is essential to conduct statistical testing on cell 
viability, death, apoptosis, and miRNA expression results. This will allow us to back 
differences and correlations statistically, potentially leading to conclusive evidence. Thus, data 
may inform the likely miRNA that may influence irradiation response in SW837 cells. 
Incorporating a cell-cycle assay using FxCycle violet stain paired with an EdU marker will be 
the next logical step to improve the understanding of how irradiation affects SW837 cells. 
Understanding the cell-cycle stage of SW837 cells will determine if irradiation is inducing 
death, apoptosis, senescence or repair. This can be used as an indication of the severity of 
irradiation damage. Furthermore, it can indicate the cell cycle time to adjust the incubation 
times to produce discernible differences.  
Additionally, the 72-hour incubation time was considered the minimal time to see discernible 
differences in cell viability, apoptosis, and death. However, extending this incubation time 
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further is a logical next step to ensure the greatest differences are seen in the cellular response 
to irradiation.  
Conducing a western blot to detect γ-H2AX using sufficient protein loading using the original 
western blot protocol should be conducted first. If this fails to provide sufficient banding, 
troubleshooting by altering the loading control to α-tubulin should be conducted. Furthering 
this, reattempting the previous troubleshooting and optimising steps with increased protein 
loading should be conducted. Additionally, staining the blotting paper with more newly made 
antibodies should be conducted. Lastly, attempting to stain another cell line that is known to 
work with γ-H2AX antibodies can be conducted to determine if the γ-H2AX antibody is 
functioning. 
miRNA expression assays in response to irradiation of SW837 cells should be conducted again 
with more repeats. If a difference is found in the miRNA expression to irradiation, additional 
assays could be conducted to determine how miRNA is related to the irradiation response. First, 
a specific miRNA mimic or inhibitor could be used to increase/ decrease miRNA expression 
and function. This paired with the cell viability, death, apoptosis and γ-H2AX assays can be 
used to determine how different expressions of miRNA influence SW837 response to 
irradiation. Secondly, the production of an SW837 irradiation resistant cell line can be 
produced to determine how the miRNA expression is altered. Using these next steps can lead 
to an understanding of how specific miRNA convey an irradiation response, either resistance 
or sensitisation. 
4.9 CONCLUSIONS 
Overall, this study demonstrated optimised methods for determining irradiation-induced cell 
viability. Specifically, demonstrating the need for prolonged incubation times to allow for the 
cells that survived to proliferate, resulting in a greater difference between irradiation doses. 
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Cell death and apoptosis determined by flow cytometry needs to undergo further optimisation 
to demonstrate the differences between irradiation accurately and to ensure all dead and 
apoptosing cells are captured for analysis. This may be done by collecting the media from 
irradiated flasks to record all apoptotic and dead cells. 
Lastly, this study found miRNA-185-5p to decrease expression when exposed to greater 
irradiation doses.  This may represent current literature which found miRNA-185-5p to induce 
radiosensitivity (55). miRNA-23a-3p demonstrated a slight increase in expression with 
increased irradiation dosing compared to 2 Gy. While miRNA-26-5p and miRNA-25-3p did 
not show any change in expression with changing irradiation dosing. However, all miRNA 
results could not have statistical analysis conducted due to the limited replications. Though, 
this study provides optimised assays to allow for future research regarding rectal cancer cell 
line irradiation. Additionally, it provides a guide to which miRNA should be researched further, 
including additional assays that will need to be conducted to give greater information regarding 
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